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I. History-taking 
Diagnosis begins with questioning on previous diseases that is medical 
history taking. Typical questions for history-taking are listed below. 
l/ Chief complaint 
- What is the main reason for the patient's visit? 
- What is the duration of the disease? 
- What factors provoke the disease? (stress, infections, drugs, food, 
allergens or others) 
- What is the course of the disease? (relapses and remissions) 
2/ Present illness 
- What are the patient's feelings (itch, pain, numbness or burning sensation 
or just a cosmetic defect) 
- What is the intensity of pathological sensations? 
- Are there systemic symptoms (e.g. high fever, fatigue, joint pain, muscle 
pain, insomnia)? 
- How did the lesion progress? (What factors aggravate the disease? Does 
it worsen at night?) 
- How does the lesion spread? (Is it spreading? Does it occur and disappear 
rapidly?) 
3/ Family history 
- Did any family members have similar symptoms? (Check the hereditary 
and allergic background of the patient) 
4/ Past history 
- Is there an associated pathology (comorbidity)? 
- What was the previous treatment of the disease? (Systemic and topical 
therapy, their efficacy) 
Primary lesions (diagnosis of many of skin diseases is based on the 
definition of primary morphological lesions). 
Macule is a localized change of skin color: "A blind man cannot find a macule". 
Possible colors and their common causes: 
red: hyperemia (erythema), telangiectases (small dilated vessels), leakage of blood 
(purpura, petechiae, ecchymosis, suggillation), 
blue: cyanosis, hematoma (black eye), dermal melanin, 
brown: dennal and epidennal melanin, hemosiderin 
white: anemia, vasoconstriction, loss of melanin, 
yellow: carotenoids, bile, solar elastosis, 
grey-black: epidennal melanin, heavy metals, tar. dithranol, foreign bodies. 
Petechiae are pinpoint hemorrhagic macules. 
Patch a broad more than 1.0 cm, flat lesion 
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Papule (S 5 mm in diameter) is a palpable lesion, caused by increased thickness in 
epidermis, papillary dermis, or both. 
Plaque is an elevated broad lesion more than 1.0 cm in diameter. 
Nodule is a dome-shaped solid indurated lesion between 1.0 cm and 2.0 cm in 
diameter formed by cells, deposits, or elements of connective tissue and and a 
thicker and deeper than a papule. Nodule is the deepest primary lesion. 
Urtica (hive, wheal) is a evanescent pink papule or plaque that often has 
pseudopods at its periphery and blanches on diascopy whis is caused by localized 
dermal edema). 
Pustule is an elevated, circumscribed collection of pus (neutrophils and necrotic 
debris ofneutrophils). Most of skin pustules are infundibular rather than superficial 
epidermal, and most of them are idiopathic. A lot of the latter are infectious, e.g., 
bacterial (staphylococci). fungal (dermatophytes), viral (herpes), and spirochetal 
(Treponema pallidum). Pustules can be secondarily developed (from vesicles). 
Vesicle is a small blister (S5 mm), filled with clear fluid. A vesicle may be 
intraepidermal (herpes virus), subepidermal (dermatitis herpetiformis). or both 
intraepidermal and subepidennal (erythema multiforme, fixed drug eruption). 
Clinically, it is often impossible to distinguish an intraepidermal vesicle from a 
subepidermal one. 
Bulla ( 2:.5 mm) is filled with clear fluid. The terms vesicle and bulla are subsumed 
by the word "blister". 
Secondary lesions (develop after primary morphological lesions) 
Ulcer is a loss of the entire epidermis and at least some of the dermis, sometimes 
even extending into the subcutis. 
Erosion, by contrast, is a superficial injury of the tissue. Results from partial or 
total loss of the epidermis, but none of the dermis. 
Scale is a collection of comified cells seen clinically as a dry, thin flake which may 
assume various sizes, shapes, and colors. 
Scale-crust is a combination of scale (comified cells. usually parakeratotic ones) 
and crust (serum that contains blood cells, either red, white, or both) 
Scar is a type of fibrosis that represents the end stage of an inflammatory process 
that early in its course resulted in destruction of preexisting tissue. evolved through 
granulation tissue, and eventuated in fibroplasia . 
Excoriation is a defect extending into dermis , caused by scratching. 
Fissure is a linear defect that extends from the surface of the skin into the dennis. 
Fissures tend to occur over flexural folds, especially on palms and soles affected 
severely by hyperkeratotic conditions such as psoriasis, congenital keratoderma. 
hyperkeratotic exzema, hyperkeratotic form oftinea pedis (manum). 
Crust is a serum that contains blood cells, either red, white. or both 
Lichenification is a thickening of the skin secondary to rubbing forcefully for 
many months or years. The condition is typified clinically by accentuation of 
nonnal skin markings, hyperpigmentation, and induration of variable extent. 
Specific terms and conditions on the skin 
Atrophy - reduction in amount of tissue is a result of there being fewer cells and/or 
smaller cells and/or amount of extracellular substances. 
Telanglectasia - a condition characterized by abnonnal, permanent dilation of 
venules mainly but also, at times, of capillaries and anerioles. 
Sclerosis - clinically, a condition of hardness of the skin (morphea). 
Sinus - an epithelium-lined channel in the skin that opens on the surface, usually 
through an infundibular ostium. In contrast to a fistula that is open on both ends a 
sinus is open at one end only. 
Tumor - a dome-shaped solid or cystic lesion more than 2.0 cm in diameter and 
fonned by cells, fluid, deposits, or elements of connective tissue. Tumors in skin 
are usually neoplasms and, less often, cysts. Rarely they are inflammatory diseases 
of the skin, exceptions being some lepromas of leprosy and giant dennatofibromas. 
Burrow - a tunnel, usually in the comified layer or spinous zone of the epidermis, 
fashioned by a parasite. 
Comedone - a dilated infundibulum stuffed by cornified cells arranged compactly 
or in laminated fashion. sebaceous secretion, and microorganisms. bacteria, yeasts. 
and mites of the normal skin flora . Comedones are nearly invariable in acne 
vulgaris, where they are characterized clinically by dark casts of dilated 
infundibula dubbed by the laity "blackheads" . 
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A detailed description of the leions is necessary for an accurate diagnosis. 
Number of eruptions: single or multiple. 
Eruption shape: round, oval, polygonal, irregular, linear, circinate: arched or 
rounded border, annular: circular or ring-shaped, discoid, nummular: disk or coin-
shaped, serpiginous:winding, twisting (snake-like), iris or cockade (target-like). 
Shape of elevation: flat, domed, umbilicated, linear. 
Eruption surface: smooth, rough, warty, papillary, granular, lichenoid, dry, moist, 
scaly, crusted. erosive, ulcerative, atrophic, shiny, necrotic, elevated. 
Eruption color: colored, depigmented, hyperpigmented, pale, anemic. 
Eruption texture: soft, firm, fragile, tense, elastic, movable. 
Eruption distribution: localized, widespread, diffuse, centrifugal, linear 
(following a line), symmetrical, asymmetrical, grouped, isolated from each other, 
lines of Blaschko (invisible under normal conditions): following embryologic skin 
lines (see jig.2), reticular( net-like), grouped, herpetiform (arranged in clusters, 
grape-like), zosteriform: following a dermatome (see .fig. 3), disseminated 
(randomly distributed). 
Eruption progress: rapid or gradual, with or without recurrence. 
Eruption border: sharp (well-circumscribed) or vague (blurred). 
Some methods of examination of a dermatological patient the doctor can 
perform by hands with minimal equipment (magnifying glass, dermatological line). 
Methods of examination in dermatology 
Diascopy 
The type of the macule could be diagnosed (inflammatory or pigmented or 
hemorrhagic ). 
In diascopy, a site with a skin lesion is pressed with transparent glass to see 
whether the coloration of the lesion disappears. If it so, the diagnosis is 
inflammatory macule (erythema). Otherwise, the diagnosis is purpura 
(hemorrhagic macule) or pigmentation macule (hypo or hyperpigmented). The test 
is also effective for distinguishing between nevus anemicus and hypopigmented 
macule. In the case of the latter, the whitish macule remains visible under the 
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pressure of diascopy. Also this method could be used for producing some specific 
phenomens like" apple-jelly symptom" in lupus vulgaris) (see.fig I). 
Inspection and palpation 
Physical examinations might be conducted in a bright room. It is preferable to 
examine the entire body skin and visible mucous membranes. The doctor can find 
the rashes and terms used to describe the nature and feature of eruptions are listed 
below. 
Scratching 
This method is usually used for the diagnosis of the presence of scaling or/and 
the type of scales and for the detection of specific symptoms of skin diseases 
(psoria~is- Auspitz sign). 
Dermogra phism 
The term dermographism literally means writing on the skin (5eejig.4. 5. 6) . 
Firm stroking of the skin produces an initial red line (capillary dilatation), followed 
by an axon-reflex flare with broadening erythema (arteriolar dilatation) and the 
formation of a linear wheal (transudation of fluid/edema) termed the triple 
response of Lewis. An exaggerated response to this constitutional whealing 
tendency is seen in approximately 2-5% of the population and is termed urticarial 
dermographism. In a minority of people, it is accompanied by itching 
(symptomatic dermographism ). 
The doctor must point out some particularities of the skin of different races. 
Classification of race by the skin 
The classification into racial groups allows an examination of the genetic 
and environmental influences on human morphology and on disease. Little is 
known about how the races originally differentiated and why they assumed their 
own characteristics. Classification of races have relied on various physical 
characteristics such as stature, cephalic index, nasal index. prognathism, capacity 
of the skull, hair texture, hairiness, skin colour, hair and eye colour, and other 
special traits such as the epicanthic fold of the eyelid (a Mongoloid feature) or 
steatopygia (a heavy deposit of fat in the buttocks, seen in Bushmen and Hottentot 
women) and is follows: 
I. Australoid: Australian aborigines, Melancsians, Papuans and Negritos. 
2. Capoid: Bushmen and Hottentots. 
3. Caucasoids: Europeans, peoples of the Mediterranean, Middle East and most 
of the Indian subcontinent, and the Ainu of Japan. 
4. Mongoloids: peoples of East Asia, Indonesia and Polynesia, native 
Americans and Eskimos. 
5. Negroids: black people and pygmies of Africa. 
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Some racial features of the skin 
Pigmentation 
The skin colour depends on the content and distribution of melanin in the 
epidennis. In Caucasoids it is darkest on the upper thigh and lightest on the lumbar 
area, whereas in black Africans the abdomen is the darkest. Males are normally 
darker than females in both races. The geographical distribution of racial 
pigmentation correlates with the areas of greatest sun exposure, although native 
Americans (Mongoloids) who lived on the whole continent of North America have 
a similar pigmentation. There are differences in size, distribution and shape of 
melanosomes. In Caucasoids, the melanosomes are small and aggregated in groups 
of three or more within a membrane in the keratinocyte and are broken up by 
lysosomal enzymes before reaching the stratum comeum. In black Africans and 
Australoids, the melanosomes are larger, distributed singly within keratinocytes, 
and persist up to the stratum corneum that is why the minimal erythema dose in 
black African skin is about 33 times as much as that for Caucasoid. Pigmented skin 
protects against sunlight and particularly against sunburn and skin cancer, but the 
disadvantages of a pigmented skin are increased heat absorption and reduced 
vitamin D synthesis. 
Normal hyperpigmentation 
Hyperpigmentation of the palms and soles 
Discrete, ill-defined or mottled macular pigmentation is frequently seen on the 
palms and soles of African patients, especially those with a darker skin colour. 
Midline bypopigmentation 
This appears as a line or band of hypopigmentation, or as discrete oval macules, 
on the anterior chest and mid- sternal area. Lesions sometimes extend down to the 
abdomen or up to the neck, where lines ofhypopigmentation may radiate out to the 
clavicles. It is commonly seen in black African males, but may occur in other 
races. 
Mongolian spot (congenital dennal melanocytosis) refers to a slatey brown or 
blue-grey mac-ular pigmentation observed at birth or in the neonatal period is 
present in 100% of Mongoloid babies, between 70 and 96% Qf black Africans, and 
in up to 10% of Caucasoids and normally located over the sacral area, but the 
buttocks, flank or shoulders may be involved. 
Nail pigmentation 
Longitudinal bands of brown or black pigmentation may be seen frequently on the 
thumb and index fingernails. They are present in more than 50% of black Africans 
and increase with advancing age. 
Oral pigmentation 
Oral macular pigmentation is seen in black Africans. It most often affects the 
gingivae, but may also involve the hard palate, buccal mucosa and tongue. 
Variations of normal pigmentation 
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Futcher's or Voigt's lines are demarcated bilateral lines of pigmentation that are 
seen at the anterolateral junction usually of the upper anns from extensor to flexor 
surface. The lines correspond to a dermatome. A second hyperpigmented line may 
occur on the postero-medial part of the lower aspect of the limbs. 
Hair 
The morphology and chemical composition of hair is similar in all races but there 
are four hair types a straight, wavy, helical and spiral. In Caucasoids, the hair 
may be straight, wavy. or helical and round or oval in cross-section but it is the 
thinnest in diameter of all the races. Mongoloid hair is usually straight. circular in 
cross-section, and with the largest diameter of all the races. The hair in black 
Africans and Capoids tends to be short, helical or spiral, flattened or elliptical in 
cross-section. and midway between the Mongoloid and Caucasoid in thickness. 
Black African hair tends to be drier and more brittle than the hair of other races. 
Mongoloids have less body hair than Caucasoids, with black Africans and Capoids 
occupying an intermediate position. 
Specific symptoms in dermatology 
Nikolsky's sign 
Is a clinical dermatological sign, named after the Russian physician Pyotr 
Nikolsky (I 858- 1940). The sign is positive when slight rubbing of the skin results 
in exfoliation of the outermost layer. Nikolsky's sign is almost always present in: 
Toxic epidermal necrolysis (TEN), Pemphigus vulgaris, Epidermolysis bullosa 
Staphylococcal scaled-skin syndrome (SSSS). It is useful in differention between 
pemphigus vulgaris (where it is present or positive) and bullous pcmphigoid 
(where it is absent). 
Asboe-Uansen sign 
It is also known as "indirect Nikolsky sign" or "Nikolsky II sign" refers to the 
extension of a blister to adjacent unblistered skin when pressure is put on the top of 
the bulla. 
Koebner phenomenon 
The "isomorphic response" means the appearing of specific skin lesions on the 
site of skin injury. As a rule lesions have linear distribution. The most common 
skin disorders with Koebner phenomenon are psoria5is. lichen nitidus, vitiligo, 
lichen sclerosus, kaposi sarcoma, warts . Warts and molluscum contagiosum lesions 
can be spread in linear patterns by self-scratching ("auto-inoculation"). 
Auspitz's sign 
It is used in the psonas1s diagnosis. This sign is being performed during 
scraping with the slide, when scales exfoliate, pointed bleeding is quickly 
produced . 
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Wickham net 
There are whitish lines visible in the papules of lichen planus, typically the 
macroscopic appearance of the histologic phenomenon hypergranulosis, and 
named for Louis Frederic Wickham. 
Dennie-Morgan fold 
It is also known as a Dennie-Morgan line or an infraorbital fold, it is a fold or 
line in the skin belo\\- the lower eyelid caused by edema in atopie dermatitis. The 
presence of Dennie-Morgan folds is used as a diagnostic marker for allergy. 
«Apple-jelly» symptom 
Diascopic examination of lupomas (tubercules) gives an apple-jelly appearance 
(yellow-bro\\-nish color of grains). rhis symptom is positive in cutaneous 
tuberculosis (lupus vulgaris) and in sarcoidosis of the skin (see fig I ) . 
In addition to clinical examination, laboratory testing helps the doctor in the 
disease diagnosis. 
Lab examinations in dermatology 
Fungal examinations 
Potassium hydroxide (KOH) is used for observation and detection of fungi 
and mites (see fig. 7,8,9). Scales or blister contents are swabbed and applied to a 
glas~ slide onto which 20% KOH solution is dripped. and a slide cover is placed on 
the top. The slide is heated on a hot plate at 70° C to 80° C for 5 -10 minutes. The 
components of the skin such as the horny cell layers are hydrolyzed, and the fungal 
components become easily . By similar procedure, parasites such as mites 
(sarcoptes scabiei - scabies) are observed. 
Cytological diagnosis (Tzanck test) 
I. Herpes infection diagnosis (herpes simplex, herpes zoster) 
It is conducted by apllying a slide glass to the bottom of erosion or the content 
of a vesicle and staining the adhered cellular components in Giemsa for 
observation under a light microscope. Ballooning keratinocytes produced by viral 
infection arc observed. They look like multi nucleated giant cells ("Tzanck cells" ) 
(see fig I 0) . 
2. Pemphigus diagnosis 
It is conducted by apllying a slide glass to the bottom of a broken blister and 
staining the adhered cellular components in Giemsa for observation under a light 
microscope. Acantholytic cells called Tzanck cells are observed in pemphigus. 1 he 
term "'acantolytic cell"refers to an epithelial cell that has undergone dyshesion (i .e 
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separation from another epithelial cell) by dissolution of intercellular bridges and 
has consequently become round (see.fig. I I) . 
Wood light examination 
A Wood's lamp is a mercury vapor ultraviolet lamp with a filler of barium 
silicate glass with 9% nickel oxide. The Wood's lamp mainly emits ultraviolet 
light in the wavelength of360 nanometers. 
Table I. Wood light examination in different skin disorders 
It should be noted that Tricophyton tonsurans and Tricophyton violeceum 
types of ringworm do not fluorescence. 
Dermatoscopy (also known as dermoscopy or epiluminescence microscopy) 
is the examination of skin lesions with a dermatoscope. This traditionally consists 
of a magnifier (typically xl 0), a non-polarized light source, a transparent plate and 
a liquid medium between the instrument and the skin, and allows inspection of skin 
lesions unobstructed by skin surface reflections. This instrument is useful to 
dermatologists in distinguishing benign from malignant (cancerous ) lesion~. 
especially in the;: diagnosis of melanoma (see fig I 4). 
Ultrasound examination of the skin 
During the past I 0 years, sonography of the skin has gained increasing 
importance as a noninvasive imaging method in dermatology. Ultrasound in 
dermatology is a non-invasive tool for the detection and verification of tumours in 
skin, subcutaneous tissues and in lymph node basins. Clinical applications are the 
preoperative determination of the extension of skin tumors, the monitoring of 
inflammatory lesions, and the objective judgement of patch test reactions . A main 
drawback of the commercially available scanners, which use transducers with 
center frequencies of 20- 25 MHz, is their limited resolution of about 80 µffi axially 
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and 200 ~m laterally. Sonograms of nomial skin (see fig 15.) show at their upper 
border a thin. very echorich line, the so-called entry echo. Below, a broad, echorich 
band with scattered reflexes is seen, which corresponds to the dermis. This is 
followed by the echolucent subcutaneous fat with its echorich connective tissue 
septae. The epidermis cannot be visualized, and certainly structures within the 
epidermis cannot be differentiated. 
Indications for ultrasound examination in dermatology: melanoma.basal 
cell carcinoma, neavi, epidermal cysts, seborrheic keratosis. angiomas, benign 
tumors and pseudotumors of the nail, connective tissue diseases: scleroderma. 
Pathology examination remains the ultimate gold standard for diagnosis of 
skin tumors. However. it is not conceivable to remove every dry skin lesion. 
Clinical examination (possibly assisted by dermoscopy) is often sufficient to 
determine whether a lesion ha~ to be removed. However, ultrasound imaging 
provides additional information such as depth and lateral delimitation of the lesion, 
homogeneous or heterogeneous structure, and hypo- or hyperechoic appearance. 
These elements may of themselves be effective in terms of diagnostic accuracy and 
they are also valuble in the initial management or surveillance of patients. 
An ultrasound examination of superficial tissues may be an adjunct tool for 
evaluating the progression and/or severity of rheumatic diseases in their primary or 
secondary manifestations. 
Confocal laser scanning microscopy 
The confocal laser microscope is a noninvasive tool for imaging skin lesions 
and subsurface skin lesions that are not visible to the naked eye or even by 
dermoscopy. Skin can be imaged in viva or freshly biopsied (in vitro ) skin 
specimens can be visualized immediately without routine histopathology. Dynamic 
events (real time imaging) in the epidermis, papillary dermis and superficial 
reticular dermis to a maximum depth of 350 mm below the stratum comeum can 
also be visualized. lt has potential for diagnosing skin lesions with precision and 
could also become a tool for monitoring treatments in some cases. 
The mechanism of its action is based on the principle that when a diode laser 
beam is passed through the skin, reflected light is used to construct detailed images 
of optical sections through the tissue. The laser light is reflected from a dichroic 
mirror. 
Indications in dermatology: 
I. Microscopic analysis of skin structures (including hair and nails) and 
components at different anatomic sites and in different conditions both 
physiological and pathological. 
2. In viva imaging of skin lesions and their margins minimizing the need for 
skin biopsy. 
3. To detect malignant changes in actinic keratoses and other premalignant 
conditions and to diagnosis of melanoma in situ. 
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4. For diagnosis of dcrmatophytc infections, to identify fungal hyphae within 
the stratum comeum after potassium hydroxide application. 
5. For in vivo noninvasive visuali7.ation of mite, Sarcoptes scabiei. 
6. To monitor treatment for skin disorders 
7. To visualize dynamic events at the cellular level in conditions like allergic 
contact dermatitis, folliculitis etc. 
8. In vivo imaging of intradermal tattoos for accurate laser treatment. 
9. To study the hair abnormalities in trichothiodystrophy. 
10.To study Merkel cell carcinoma. 
I I .To quantify the number of Langerhans cells and other epidermal cell nuclei 
per volume unit in skin biopsies. 
CLS is a rapid, noninvasive technique allowing early diagnosis and 
management and high resolution images as compared to computer tomographal 
scaning, MRI and USG for dermatological use. Disadvantages of confocal 
microscopy include its high cost and relatively smaller field of vision. 
Optical coherence tomography 
Histology represents the gold standard for morphological investigation of the 
skin, though biopsy may alter the original morphology, is non-repeatable on the 
same site and always requires an iatrogenic trauma. In the past decade, advances in 
optics, have enabled the development of a novel non-invasive optical biomedical 
imaging technique, optical coherence tomography (OCT). The latter is based on a 
classic optical measurement method known as low-coherence interferometry that 
enables non-invasive, high resolution, two- or three-dimensional, cross-sectional 
imaging of microstructural morphology in biological tissue in situ. Using 
conventional OCT with a lateral resolution of 10-15 µm, the stratum comeum of 
palmoplantar skin, the epidermis and the upper dermis can usually be identified, as 
well as skin appendages and blood vessels. For example, non-invasive monitoring 
of cutaneous inflammation, hyperkeratotic conditions and photoadaptive processes 
is possible by means of OCT. Furthermore, the development of high-output 
broadband light sources potentially allow the differentiation between benign and 
malignant tissues. Beyond a high resolution morphology in OCT images, tissue 
characterization by additional local physical parameters, such as the scattering 
coefficient and refractive index may be of great value, in particular in cosmetics 
and the pharmaceutical industry. Therefore. the advanced versions of OCT 
technique might not only lead to significant new insights in skin physiology and 
pathology, but also in diagnosis and therapeutic control of cutaneous disorders 
with respect to non-invasive diagnosis of conditions and monitoring of disease 
activity in addition to treatment effects over time. 
lmmunotluorescence testing is important for diagnosing immunobullous 
diseases. connective tissue diseases and vasculitis 
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Direct immunofluorescence (DIF) involves the overlay of fluorescein-
conjugated antibodies (lgG, lgM, lgA), complement (C3 ), and fibrinogen onto 
frozen sections of tissue obtained from patients. Biopsy specimens for direct 
immunofluorescence in immunobullous diseases should be taken from perilesional 
normal-appearing skin within a few millimeters of the edge of the blister. However 
when a biopsy specimen is needed for diagnosis of connective tissue disease or 
vasculitis, a lesional biopsy is optimal (see fig.16. 17, 18, 19) 
Table 2. Direct immunofluorescence (DIF) in some inflammatory skin 
disorders 
fTheshlndlseas;--~oeM"i~ion - -The site of deposition I 
; Pemphigus vulgaris lgG, --tfntercellular (around keratinocytes of 
I 
C3 I stratum spinosum) I 
--------~l_c_o_m~plement I __ _ _ _ _ 
J Bullous pemphigoid '1 IgG, iLinear in the epidermal basement I 
I C3 i membrane 1 
f I complement i 
I Herpetiform dermati~A ;]ranular deposition on the papillar , r-------- - --- _  lr----·c__ _ _ _ layer in derma _ _ _ J 
I 
Lupus erythematosus IgG, IgM Linear on the basement membrane 
, and around hair follicules 
rvasculitis lgM, lgG, C3, I Strong dermal blood vessels 
L_ __ fibrinogen _ _ _L_ 
Indirect immunofluorescence studies involve the detection of circulating 
autoantibodies in the patient's serum which target specific antigens in the patient's 
skin or mucosa. The technique for indirect immunifluorescence is helpful in 
immunobullous diseases. It includes incubation of patient's serum, which contains 
the antibodies with frozen sections of epithelial substrate. The substrate is usually a 
monkey esophagus, but a pig esophagus also may be. The rat bladder is used to 
rule out paraneoplastic pemphigus. After washing, the fluorescein-labeled animal 
anti-lgG-conjugate against human immunoglobulin, such as IgG is added. This 
lluorescein-labeled animal conjugate binds to the patient's circulating IgG, which 
is already bound to the target antigen on the epithelium surface. 
The serology test is also used in dermatology for the detection of antibodies 
to syphilis and HIV. 
Skin biopsy 
Biopsy (from the Greek bios meaning 'life' and opsis 'sight') of skin lesions 
is useful to establish or confirm a clinical diagnosis. A piece of tissue is removed 
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surgically for histological examinalion and sometimes for other tesls (e.g. culture 
for organisms). 
Indications for biopsy: 
• You cannot make a diagnosis; 
• The disorder does not respond to treatment; 
• The disorder is unusual or severe; or 
• You are just not sure. 
Biopsy Technique Selection 
Six major methods are employed to biopsy skin: curettage, snip or scissors biopsy. 
shave biopsy, punch biopsy, incision biopsy, and excision in toto. 
Curettage is frequently used to remove clinically benign epidermal lesions, a 
curette 3- 5 mm in diameter is held like a pencil and drawn with pressure under the 
lesion (if epidermal) or through the lesion (e.g. presumed BCC). 
Snip or scissors biopsy is an efficient technique for assessing pedunculated lesions 
as well as removing benign growths (e.g. acrochordons, filiform warts). 
The shave biopsy usually provides a specimen consisting of epidermis, papillary 
dermis and, sometimes, reticular dermis (particularly in elevated lesions). It is a 
popular biopsy technique for 'planing' papular, clinically benign lesions (e.g. 
irritated or unwanted compound and dermal melanocytic nevi, fibrous papules of 
the nose) where histological confirmation is desired, also a useful procedure for 
diagnosing superficial carcinomas, lentigo maligna. 
The punch biopsy supplies a cylindrical - to conically shaped specimen consisting 
of epidermis, dermis and, sometimes, subcutaneous fat. The volume of tissue 
sampled correlates with the size of the punch biopsy instrument. In general, the 
diameter of the metal 'barrel' varies from 2 to 6 mm, and the wider the diameter, 
the greater the likelihood of obtaining subcutaneous fat. 
The incisional biopsy removes a wedge of tissue from the centcr or edge of a 
lesion and is the best option for obtaining deep subcutaneous fat or fascia for 
histological examination. It is also used to sample a significant portion of large-
sized tumors. 
Excision in toto removes the entire lesion and includes epidermis, dermis and 
subcutaneous fat. For these reasons, it is often the biopsy of choice for a presumed 
invasive cutaneous melanoma 
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Specimen Handling 
Transportation of the biopsy specimen to the laboratory differs according to 
the processing and type of examination required. Most specimens are placed in 
10% formalin, but, occasionally, special carrier media are necessary, e.g. Michel's 
medium for direct immunofluorescence. Fresh tissue specimens for direct 
immunoOuorescence, immunoperoxidase, culture for bacteria, mycobacteria or 
fungi are sent on saline-moistened gauze and either promptly delivered to the 
laboratory or packed in ice; the laboratory must be in reasonable proximity and 
have the capability of processing the tissue immediately. For culture for viruses 
viral transport medium is necessary. 
Site Preparation and Anesthesia 
Marking the site, cleansing the skin, and draping are important procedures 
prior to the instillation of local anesthesia. Local anesthesia is adequate for all skin 
biopsies. The agent generally used is lidocaine, either at a l % or 2% concentration. 
Epinephrine may be added to the lidocaine in order to reduce bleeding and prolong 
anesthesia, but it is avoided in patients who have a proclivity for cardiac 
arrhythmias. Topical agents include eutectic mixture of local ancsthetics (e.g. 
EMLA® with lidocaine and prilocainc), tctracaine, liposome-encapsulated 
tetracaine, and liposomc-encapsulated lidocaine. 
Hemostasis 
All methods of biopsy require attention to hemostasis of the wound bed. For 
small-diameter, superficial wounds, compression alone may be used. Styptics such 
as aluminum chloride hexahydrate (Drysol™, Xerac AC™) and ferric subsulfate 
(Monsel's solution) arc frequently used. Punch biopsy sites are usually closed 
primarily and the suturing itself creates sufficient hcmostasis. Wounds created 
during incisional biopsy or excision in toto may require electrocoagulation for 
hemostasis before closure. 
Histological terms (glossary) 
Abscess is a localized collection of neutrophils. An abscess may form in the 
epidermis, both surface and infundibular, eccrine ducts, dermis, and subcutaneous 
fat, or in parts of any other organ and it may come into being by virtue of infection 
or independent of it. 
Acantholysis is a consequence of loss of connections (desmosomes) between 
epithelial cells, separating from one another, becoming round and eventually 
dying. The process ends in formation of either a cleft or a blister. 
Acanthosis is an increase in thickness of the epidermis consequent to an increase 
in thickness of the spinous (prickle, malpighiian) zone secondary usually to an 
increase in number of cells. 
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Atrophy is a reduction in amount of tissue as a result of there being fewer cells 
and/or smaller cells and/or amount of extracellular substances. Atrophy can affect 
the epidermis, the dermis, and the subcutaneous tissue, and the skin and 
subcutaneous fat together. 
Ballooning is an "intracellular edema" of epidermis and epithelial structures of 
adnexa, recognizable morphologically as swollen pale cytoplasm of affected 
spinous cells. Rupture of decidedly ballooned keratocytes leads to formation of a 
pattern of epidermis that resembles a net and, therefore, is termed reticular 
alteration. 
Basement membrane is situated between dermis and epidermis. 
Cleft is a space that does not contain fluid. A cleft may appear within the 
epidermis, below the epidermis, between epithelial cells and adjacent stroma. 
Dermoepithelial interface is the junction between dermis and epithelial structures 
contiguous with it, e.g., epidermis (surface and infundibular) and adnexal 
(folliculosebaceous-apocrine and eccrine). 
Dyskeratosis is an abnormal comification of individual keratocytes within the 
epidermis and epithelial structures of adnexa. Dyskeratotic cells have pyknotic 
nuclei and eosinophilic cytoplasm as visualized by electron microscopy. 
Fibrosis is a formation of abnormal fibrous tissue characterized usually by an 
increase in number of fibrocytes, an increase in amount of collagen, and an 
aberration in the structure of collagen as it is assessed by conventional microscopy. 
Granuloma is a collection ofhistiocytes, usually epithelioid ones. 
Hypergranulosis is an increased thickness of the granular zone of an epidermis, 
surface and/or infundibular, or of the upper part of an eccrine (or theoretically, an 
apocrine) duct as a consequence of an increased number of keratocytes whose 
cytoplasm contains keratohyaline granules. 
Hyperkeratosis is a thickened comified layer of an epithelium, usually an 
epidermis (surface and infundibular), but sometimes the upper part of an eccrine 
duct (and, theoretically, an apocrine duct). Hyperkeratosis may be classified as 
either orthokeratosis, in which no nuclei are visible in comified cells, or 
parakeratosis, in which nuclei are retained overtly by comified cells. 
Infiltrate is the presence of elements in tissue in a quantity greater than normal. 
An infiltrate may be cellular (lymphocytes or neoplastic cells) or noncellular 
(mucin, colloid). Noncellular infiltrates are referred to as deposits. 
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Karyolysis is a disappearance of nuclei from cells during the process of cell 
death. Karyolysis (ghosts of nuclei), karyorrhexis (fragmentation of nuclei), and 
pyknosis (shrinkage and darkening of nuclei) are the three cardinal signs of 
necrosis. 
Lamina densa is studied by electron microscopy (basal keratocyte, tonofilaments, 
hemidesmosome, lamina lucida). 
Spongiosis is an "intercellular edema" of the epidermis and of epithelial structures 
of adnexa, expressed morphologically by widened spaces between spinous cells 
and by intercellular bridges that stretch across those extended spaces in company 
with inflammatory cells ones. 
Vacuolar alteration is a tiny space on either side of. a basement membrane 
situated at the dermoepidermal junction and at the junction of dermis and epithelial 
structures of adnexa. 
Skin tests 
The patch test is the most frequent test for detection of specific substance causing 
allergic inflammation of the skin. A patch test relies on the principle of a type IV 
hypersensitivity reaction. 
The general rule for patch testing: 
• Complete healing or remission need to be done before patch testing 
• A void patch testing on markedly tanned persons 
• Do not test pregnant women 
• The preferred site is the upper back 
• Clip hair one or two days before patch testing 
• Patients should be informed as to the aim of the test: about avoidance of 
showers, wetting the test site, irradiation and excessive exercise, and about 
symptoms such as itch and discomfort. 
The standard patch test technique involves application of the test allergen strips 
to the skin under occlusion for 48 h. Interpretation of results is performed at the 
third, 4-th days, and at the 7-th day after occlusion (i.e., 1, 2, and 5 days after the 
removal of the patch test strips). 
Table 3. Scoring of patch test reactions 
~----__fu:~re_ ·------ -- Interpretation _ ] 
, Ne ative reaction j 
Doubtful reaction; faint e~thema only_ 1· 
Weak (nonvesicular) reaction; 
e hema, sli t infiltration · 
Strong (edematous or vesicular) J 
I ?+ J--- -~+ -
t=_ ++ 
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reaction; erythema, infiltration, vesicles 
+++ Extreme (bullous or ulcerative) 
IR Irritant reactions of different types 
NT Not tested 
Other skin tests 
Stripping test is a variant of patch testing consisting of "stripping" the stratum 
corneum before applying the allergens in the usual way to suppress the skin 
barrier. 
Open test. Skin allergens are dropped onto the volar foreann and allowed to 
spread t'reely . No occlusion is used. 
Semi-Open test is a variant of the open test covered by a non-occlusive tape. It is 
thus "half-way" between open testing and conventional PT. 
Repeated open application test. Allergens are applied allergens twice daily for 7 
days to the outer aspect of the upper ann, antecubital fossa, or back skin (scapular 
area). A positive result (eczematous dermatitis) may appear on the 2-4 days but it 
is recom-ended to extend the applications beyond 7 days so as not to miss late-
appearing reactions. 
Prick test is a test method for detecting immunoglobulin E (lgE)-mediated 
allergy. Drops of allergen solutions are applied to the volar aspect of the forearm 
or to the upper part of the back. When drops of allergen solutions are applied to the 
skin, they are pierced with a special lancet for penetration of allergens into 
epidermis. No bleeding may occur. Conventional time reading is 15-20 min. Prick 
testing of allergens needs the concomitant use of controls, positive and negative. 
Histamine chlorhydrate solution and codeine phosphate solution (9%) is used as 
positive controls. Saline and/or the vehicle of the allergens is used as a negative 
control. 
Scratch test is a common method for detecting immediate allergy. It is still used 
when only non-standardized allergens are available. A scratch of approximately S 
mm long is made with a blood lancet and bleeding is avoided. The back and arms 
are the preferred test sites. Scratch testing of allergens needs the concomitant use 
of controls, positive and negative. 
Dermatological treatment 
The types of the dermatological treatment are: topical treatment, systemic 
therapy, physical therapy, surgery and dermatological treatment may be etiological 
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(known etiology of the disease), pathogenetic (known pathogenic mechanism of 
the disease) and symptomatic (reduced symptoms). 
Topical treatment is the first important step in the management of skin 
diseases.Efficiency and location of the use of topical preparations depends on the 
basis of the drug. 
Topical vehicles 
Ointments 
Ointment is semi-solid grease or oil topical vehicle with little or no water. 
Ointments are occlusive and allow for high transcutaneous penetration of the active 
drug. Ointments are stable for a long period of time. Ointment is the best 
therapeutic option in the treatment of thick infiltrates of the skin (plaques), because 
they can penetrate to the deep layers of the skin. Ointments rehydrate, moisturise, 
but because of the greasiness they are difficult to wash off. 
Powders 
Promote drying and are especially useful in the intertriginous areas but in the 
wet areas powder can form clumps. They are used in subacute process without 
weeping. 
Lotions 
Lotion is a liquid vehicle, often aqueous or alcohol-based which may contain 
a salt solution. Lotions evaporate and cool the skin - useful for inflammed and 
exudative conditions. 
Gels 
Gels are transparent semi-solid non greasy emulsion, aqueos preaparations 
that liquefy on contact with the skin and leave a uniform film on drying. Gels are 
well-tolerated in hair-bearing regions. 
Aerosols 
Aerosols and sprays act in a manner similar to lotions and gels. Active 
ingredients are incorporated into aqueous phase. A convenient delivery system 
usually allows for easy dispertion over the skin surface. Aerosols are also 
particularly useful on the erosive and ulserative lesions. 
Creams 
Creams are presented as suspensions of oil in water. As the proportion of oil 
increases, the preparation approaches the consistency of ointment, which is the 
most lubricating vehicle. Creams are not greasy and easy to remove. Effects of 
creams are cooling, vasoconstructive, antiinflammatory. They often used in dry 
skin lesions. Creams act more superficial comparing with ointments. 
Solutions 
Cooling, anti-inflammatory, antiseptic effects. The main indication for 
solutions in dermatology is wet dressings in acute excudative skin surface (eczema, 
pyoderma). 
The vehicle is prescribed according to the stage of the inflammation process. 
Acute inflammation (wepping, bright erythema, edema, erosion) - sprays, wet-
drying bandages, solutions. 
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Acute inflammation without wepping (hyperemia. swelling) - creams, 
lipocreams, pastes, aerosols. 
Subacute inflammation (swelling and hyperemia are soft, mild itching) - creams, 
lipocreams, pastes, ointments. 
Chronic inflammation (lichenification, infiltration) - hot compresses (occlusion), 
ointment, keratolytic and keratoplastic ointment. 
Hyperkeratosis (palms ahd solves) - keratolytic ointment under occlusion. 
Steroids in dermatology 
The steroids (local and systemic) are often used in dermatology. 
Table 4. Classification of topical steroids according to potency 
.--~--~~~~-,-·-~~~~~~--~~~~~~~-,.-~-~~----, 
Potency Steroid Trade Name j 
I i 
Mild jQ-1 % Hydrocortisone acetate Efcortelan ~ 
Perderm 
____Q,05% Alcometasone dipropionate 
Moderate I 0.05% Clobetasone butyrate Eumo~ 0.02% Triamcinolone acetoi;.ide ---·-- - Aristocort 
c 0.025% Fluocinolone acetonide Synalar . 0.05% Clobetasone butyrate Eurnovate I 
Potent 0.025% Beclomet~asone dipropionate Propaderm ~ 0.05% Betamethasone dipropionate Di pros one I 
0.1% Betamethasone valerate Betnovate i 
0.1 % Hydrocortisone I ?-Bu~rate Loco id I 
0.05% Halometasone monohvdratc Sicorten I 
-
I Very Potent I 0.05% Clobetasol propionate Dermovate ~. 
The USA system utilizes 7 classes, which are classified by their ability to 
constrict capillaries. Class I is the strongest, or super potent. Class VU is the 
weakest and mildest. 
Group I 
Very potent: up to 600 times stronger than hydrocortisone: 
• Clobetasol propionate 0.05% (Dermovate) 
• Betamethasone dipropionate 0.25% (Diprolene) 
• Halobetasol proprionate 0.05% (Ultravate, Halox) 
• Ditlorasone diacetate 0.05% (Psorcon ) 
Grouplt 
• Fluocinonide 0.05% (Lidex) 
• Halcinonide 0.05% (Halog) 
Amcinonide 0.05% (Cyclocort) 
• Desoximetasone 0.25% (Topicott) 
22 
Group Ill 
• Triamcinolone acetonide 0.5% tKenalog, Aristocort cream) 
• Mometasone furoate 0.1 % (Elocon ointment) 
• Fluticasone propionate 0.005% (Cutivate) 
Betamethasone dipropionate 0.05% (Diprosone) 
Group n' 
• Fluocinolone acetonide 0.01-0.2% (Synalar, Synemol, Fluonid) 
Hydrocortisone valerate 0.2% (Westcort) 
Hydrocortisone butyrate 0.1 % (Locoid) 
Flurandrenolide 0.05% (Cordran) 
• Triamcinolone acetonide 0.1 % (Kenalog, Aristocort A ointment) 
• Mometasone furoate 0.1 % (Elocon cream, lotion) 
Group V 
• Triamcinolone acetonide 0.1 % (Kenalog, Aristocort,kenacort-a vail, cream, 
lotion) 
Fluticasone propionate 0.05% (Cutivate cream) 
Desonide 0.05% (Tridesilon, DesOwen ointment) 
Fluocinolone acetonide 0.025% (Synalar, Synemol cream) 
Hydrocortisone valerate 0.2% (Westcort cream) 
Group VI 
Alclometasone dipropionate 0.05% (Aclovate cream, ointment) 
• Triamcinolone acetonide 0.025% (Aristocort A cream, Kenalog lotion) 
Fluocinolone acetonide 0.01 % (Capex shampoo, Dermasmooth) 
Desonide 0.05% (DesOwen cream. lotion) 
Group Vll 
• Hydrocortisone 2.5% (hytone cream, lotion, ointment) 
Hydrocortisone 1 % (many over-the-counter brands) 
The weakest class of topical steroids has poor lipid permeability, and cannot 
penetrate mucous membranes well. 
lntralesional steroids are used for recalcitrant dermatoses, such as alopecia, 
keloids, scars, prurigo nodularis and lichen simplex. Triamcinalon is often used, 
but dermal atrophy and leukoderma may occur. 
Steroid topical application may have side effects. Particular care should be 
taken in facial application, because of high absorptiveness of the skin there. 
Skin atrophy 
Repeated use of topical steroids in the same area can cause thinning of the 
epidermis and changes in the connective tissue of the dermis. The skin becomes 
lax, wrinkled, and shiny with visible telangiectasias, hypopigmentation, and 
prominence of underlying veins. In most cases the atrophy is reversible once 
topical steroid use is stopped, but it may take months for the skin to "thicken" back 
up. 
Tachyphylaxis 
Tachyphylaxis is the tolerance the skin which develops to the 
vasoconstrictive action of topical steroids. After repeated use of topical steroids, 
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the capillaries in the skin do not constrict as well, requiring higher doses or more 
frequent application of the steroid. The ability of the blood vessels to constrict 
returns 4 days after stopping therapy. 
Steroid rosacea 
This is a side effect commonly observed in fair-skinned people who already 
have rosacca. A typical example occurs when a person uses a very mild steroid on 
the face to counteract the facial flushing and tcleangiectasia. This gives pleasing 
results, but tolerance develops, causing the person to use a higher strength steroid. 
At this point any attempt to cut down on the steroid application or stop altogether 
cause intense facial redness and pustules. 
Striae - stretch marks 
Repeated use of topical steroids in areas where skin touches skin such as the 
groin and annpits can result in striae, or stretch marks. Stretch marks from topical 
steroids are pennanent and irreversible. It is recommended to progressively 
decrease the steroid potency until topical steroids therapy in these areas can be 
tenninated . 
Alteration of infection 
Because topical steroids change the way the immune system functions, they 
can inhibit the skin's ability to fight off bacterial or fungal infections. A !)pica! 
example of this is seen when someone applies a topical steroid to an itchy groin 
rash . If this is a fungal infection, the rash gets redder, itchier, and spreads more 
extensively than a typical fungal infection . The resulting rash is a bizarre pattern of 
widespread inflammation with pustules called tinea incognito. 
Topical steroid allergy 
Some people may be allergic to a component of the topical steroid base, or 
vehicle. Patch-testing of a group of patients with dennatitis revealed 4-5% were 
allergic to topical steroids. People who have chronic skin conditions and use 
multiple prescription or over-the-counter topical steroids are at higher risk of 
developing allergies to topical steroids. 
Glaucoma 
Glaucoma is a disease in which the pressure inside the eye increases to the 
point of damaging the optic nerve. 
As long as the doses of steroids are appropriate, systemic side effects are 
rare. However, when strong steroids are applied on a large area for a long period or 
when they are used in occlusive therapy, side effects similar to those caused by 
steroid systemic administration may be produced (table 4). Moreover special care 
should be taken in administration of steroids to infants, since side effects lend to be 
systemic. 
Table 5. Side effects of systemic steroids 
. Se~;;:;-----_ - - -- ----= i Relati;.ym~ =·=---1 
l_§econdary adrenal dys_function ffi~n face, central obesi!}'.__ __ J 
I Sideration and exacerbation ~f diabete~ H __ e.!E!iagia _ __ ____ _ _ J 
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I ~;d:~~~;;;'' ,,,C,mafio" of · -1 I <ukocytM;, 1. ~-- - - ----- -- ----- ---~-·-
! Hyperlipidemia . _ ~!n streaks =-==:] 
l f~chiatric effects ' Subcuta~~ous hemorrhag~!Pt,J!it~ 
l.Muscular atrophy Steroid acne _ _j 
!_Cataract, glauco. ma Hypertrichosis I 
Gast! ic ulcer _ ___ __ _ Alopecia - ----1 
i Osteoporosis Ede~ ----------------i I 
· Aseptic necrosis of bone Insomnia 
r Susceptibility to various infectious --
: conditions 
- ---- - -- - ------ --~----- ---
Antihistamines 
There are several types of antihistamine agents that bind to histamine receptors to 
inhibit their functions. H1 receptor inhibiting drugs, widely used in dermatological 
treatment, are extremely effective in the treatment of allergic inflammatory skin 
disorders. Antihistamines suppress the histamine-induced wheal response 
(swelling) and flare response (vasodilatation) by blocking the binding of histamine 
to its receptors on nerves, vascular smooth muscle, glandular cells, endothelium, 
and mast cells. They exert a competitive antagonism to histan1ines. Itching and 
sneezing are suppressed by antihistamine blocking of HI-receptors on nasal 
sensory nerves. 
In common use, the term antihistamine refers only to H1 antagonists, also 
known as H1 antihistamines. Antihistamines are divided into three generations. 
Sedation is a common side-effect of first generation antihistamines, such as 
diphenhydramine and doxylamine, which are also used to treat insomnia. However, 
second-generation antihistamines, such as Loratadine, Cetirizine, Fexofenadine do 
not cross the blood-brain barrier, and as such do not cause drowsiness and also 
they have a long scrum half-life. 
Hrantagonists have a stimulant and nootropic effect, and are being 
investigated for the treatment of conditions such as ADHD, Alzheimer's disease, 
and schizophrenia, whereas H4-antagonists appear to have an immun0modulatory 
role and are being investigated as anti-inflammatory and analgesic drugs. 
The main indications for H 1 antihistamines in skin are suppression of 
pruritus in urticaria and atopic eczema, both of which arc associated with increased 
mast cell numbers and tissue histamine levels. However the evidence basis for their 
use in atopic eczema is ambiguous and controversial, even though these drugs are 
widely used in practice. Currently, significant side-effects are mainly confined to 
the first-generation compounds and are especially troublesome in the elderly. 
Psychomotor impairment may persist throughout the day following administration. 
Anti-cholinergic and anti-a-adrenergic blockade and cardiotoxicity may also occur 
with first-generation antihistamines. Two early low-sedation second-generation 
antihistamines cause arrhythmias in a small number of patients but these 
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compounds have now been withdrawn (Hismanal (astemiozole). Generally, the 
second-generation H 1 antihistamines are well tolerated. 
Table 6. Systemic antihistamines 
~ ------- First generation (~edative) ·---~ 
-Brom heniramine I Dimotane -- - --------- - - - - -
Chio heniramine Piriton 
, Clemastine !I TPacnve
3
gc1
1
·1
1
.n .. _ ···- _ _ _ __ 
1 
\ Cyclohcptadine hvdrochloridc -+-- ------
Di henhydramine 
\ Hydr~zine hydroc~loride Alara". U_ce_r_ax_________ __ 1 ~o~ethazine !!}:droc~loride __ ~~n_ ~
hPromethaz.ine teoclate 
1 
Avomine -
! Trtmeprazme _ - -
Second generation (nonsedative) 
:iada) -- _ 
c,,,.,, tUKl . I 
-~~ 
Cetirizine hydrochloride Zirtek (UK) Zyrtec (US) Reactine (Ca 
Fexofenadine hydrochloride Telfast (UK~llegra (US and Canad 
Loratadine Claritin and Claritin Redi Tabs (US). 
I Desloratidine Neoclarityn (UK), ~larinex (US) 
I Levocabastine Levostin (UK) 
Mizolastine Mistamine (UK). Mizollen (UK) 
I Acrivastine Semprex (UK) 
[Levocetirizine di~ochloride Xyzal (UK) 
Side effects of antihistamines 
The frequency and severity of adverse effects will vary between drugs. Not 
all adverse reactions will apply to every member of this class. 
Table 7. Side effects of antihistamines 
Gastrointestinal HematologkTSome of the other I 
Central nervous I problems reactions \ adverse effects I 
system reactions . (rare, but may be I 
+
1
1 
_______ ,__ __ s_e_v_er_e) I I 
headac~ increased anemia chest tightness J 
insomnia a etite 
- drowsiness decreased-- leukopenia___ wheezing I 
weakness ap etite 
sedation nause_a__ _ __ bone marrow failure nasal stuffiness 
dizziness vomiting - -+---
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, dry- mouth, nose and 
I throat I sore. throat 
respiratory 
__ ±::"-=--
coordinationcl I 
....__ _ r_es_tl_e_ss_ness __ ___ ___l ____ ____ __,_ _] 
When taking antihistamines during pregnancy: chlorpheniramine (Chlor-
Trimeton), dexchlorpheniramine (Polaramine), diphenhydramine (Benadryl), 
brompheniramine (Dimetapp), cetirizine (Zyrtec), cyproheptadine (Periactin), 
clemastine (Tavist), azatadine (Optimine), loratadine (Claritin) are all listed as 
category B. Azelastine (Astelin), hydroxyzine (Atarax), promethazine (Phenergan) 
are category C. 
Regardless of chemical class of the drug, it is recommended that mothers not 
breast feed while taking antihistamines. 
Contraindications 
The following are absolute or relative contraindications to use of 
antihistamines. The significance of the contraindication will vary with the drug and 
dose: glaucoma, hyperthyroidism (overactive thyroid), high blood pressure, 
enlarged prostate, heart disease, ulcers or other stomach problems, stomach or 
intestinal blockage,liver disease, kidney disease, bladder obstruction, diabetes. 
Topical antihistamines 
Topical antihistamines are produced in creams, nasal sprays and other agents 
that can be applied locally. Fenistil gel is often used in the treatment of allergic 
skin diseases. 
Retinoids 
The retinoids are a class of chemical compounds that are related chemically 
to vitamin A. Retinoids include naturally occurring molecules and synthetic 
compounds that have specific biologic activities that resemble those of vitamin A 
or bind to the nuclear receptors for retinoids. 
There are three generations ofretinoids: 
First generation retinoids: which include retinol, retinal, tretinoin (retinoic 
acid, Retin-A), isotretinoin (Roaccutan, Accutan), and alitretinoin. 
• Second generation retinoids: which include etretinate and its metabolite 
acitretin (Neotigason). 
• Third generation retinoids: which include bexarotene, tazarotene. and 
adapalene. 
The biological functions and actions ofretinoids: 
l. Reproduction, embryonic growth, and morphogenesis. 
2. Modulation of proliferation and differentiation of epithelium. 
3. Decrease in sebaceous gland size (isotretinoin). 
4. Immunological and anti-inflammatory effects. 
5. Tumor prevention and treatment. 
6. Effect on extracellular matrix components. 
27 
Systemic treatment with acitretin is effective in several disorders of 
keratinization. Darier·s disease, ichtyosis vulgaris. congenital ichtyosis 
(particularly dry lamellar type), various types of palmaplantar keratoderma, and 
also erythrokeratodennia figurate variabilis today represent standard indications 
for oral acitretin treatment. Treatment of topical retinoids is an effective alternative 
in mild forms of these diseases and especially in Darier's disease. 
Oral acitretin belongs nowdays to the mainstream systemic antipsoriatic 
treatment, particularly in severe pustular and erythrodermic types of the disease. It 
acts on a pathological epidermis to reduce proliferation and stimulate 
differentiation. Acitretin is usually prescribed in combination with other modalities 
(mild corticosteroids, dithranol, tar, vitamin D derivates) and/or with phototherapy 
(Re-PU VA). !lalmoplantar pustulosis, psoriasis of nails, HIV-associated psoriasis 
significantly improve under systemic acitretin . In pityriasis rubra pilaris. a 
beneficial effect can be expected, especially in juvenile type of the disease . 
Oral isotretinoin is only one drug currently available that affects all four 
pathogenic factors of acne, directly suppressing abnormal desquamation of 
sebaceous follicle epithelium and sebum production. The basic patterns of use of 
retinoids are described in table 7. 
Table 8. Retinoids in Dermatology 
!Rett.~ids -Ski.1 disordel Clinical for~~- [ Recommended~~ ! lsolrrlinoin Acnr Noduloc)'sllc I O.) - 1.0 mg/kg/day p o I 
I ~ Sev~:~va::e~~=atcd I 
L___ _ _ ____ +:I cl!.~£81__5!istress 1-- __ _  __ I I lsotrttinoin Rosacea Nodulocysuc I 0-20 mg/day 1 
1 Papulo-pustular I 
1-Acitretin1 - - Psoria~- Palmo-plantar pustular 25-30 mg/day. \ 
I 
Etrrtinate I Pustular generahzied Maintenance dose. 
I 
El)throdennic 25-50mg/day may be 1 
I 
.., ..... .,, ,.,. ..~ ··~ ..... "'"""~ I 
1 to treatment ( 12-16 
~ ~t=: weeks). itre~in _ _ Lich~~lanus Oral and ~kin !Orms . I 0-30 m~day - __ retinalt Sezary syndrome with no 0.2-0.5 mg/kg\day 
r::
-- _ ____£!'En im:ol~e!!!_ent ----1 
aroten Cutaneous 300 mg/m2 day p.o. 
T-cell l}·mpboms Early IA. IB. llA stages , 
L Ali_!!:etinoin S arcoma Ka osi -=~-~- I 45 mg/m2 per daL~j 
'.._ _ __ J;pithelium tumor · __l__ _ _ =i I Acitretin I lchtyiosis I Lamcllar ichtyios1s - r t0-20 mg/day I 
I I X-lmk~d 1chty1os1s I \ IL I I Epidcnnolytic ichtyiosis 
- ___ J ____ ____ J __ _lc..!!!~~u~_!:!____L ____ _ . _ __ _ J 
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r:retin Darier Disease 0,5-1.0 mg/kg/day 
retinoin 
! Etretinate Pityriasis rubra 10-30 mg/day 
I pilaris 
Acitretin Lichen sclerosus Genitalia region 2~30 ~;,_~-j Etretinate and atrophicus localization 
- I I0-30 mg/~ Alitretinoin Chronic hand 
I 
eczema 
I ~ Seborrhea 
Topical retinoids alone or in combination today are the first line treatment of 
moderate and mild forms of acne. Tretinoin, adapalen, isotretinoin, tazarotcn are 
effective comedolytic agents. 
Topical tretinoin is effective in actinic keratosis, plane warts. 
lsotretinoin and tazaroten were found to improve photoaging skin changes. 
Epidermal melasma, actinic Jentigines, superficial postinflammatory 
hyperpigmentation also respond to topical tretinoin, either alone or in combination 
with hydroquinone and hydrocortisone. 
Table 9. Topical retinoids 
[ Substance Concentration, basis I Indications 
--~apalen (Differint 0. I % gel, solution. cream · Milcl/moderate acne 
' Alitretinoin (Panretin) 0.1 % !!.el I AIDS-related Kaposi' s sarcoma 
Bexaroten (Tar!!.etin) 0.1 %11.el I Cutaneous T-cell lvmphoma-
. -~~~--
lsotretinoin (lsotrex) 0.05% gel, 0,05, 0.1 % cream I Mild/moderate acne I Photoaging 
Tazaroten 0.005. 0, I % gel I Psoriasis, mild/moderate acne , 
(Zorac. Tazorac) 
0.025, 0 01,0.05. 0.1, 0.4% I Mild/moderate acne -1 Tretinoin (Airol, Retin A) 
cream Photoaging I 
0.025 % gel, 0.05%, 0.1, 0.2 i Cosmetic indications 
be_tinoin 
solution 
0, 1 % ointment I 
0.025% cream lnflammatorv rosacea ----i ~~--~~'--~~~-'---'-~ ~~~~~
Side effects of retinoids 
• Teratogenicity 
• Cheilitis, xerosis, skin peeling, pruritus, conjunctivitis are common. 
• Reversible abnormal results on laboratory tests: hyperlipidemia increased 
liver enzyme levels, and hypothyroidism (bexaroten). 
• Blood and lymphatic system: anemia, increased red blood cell 
sedimentation rate, thrombocytosis, neutropenia. 
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• Depression, anxiety (rare) 
• Sun sensitivity 
• Musculoskeletal and nervous system side effects are rare. 
• Headache (rare) 
• Gram positive infections (mucocutaneous), bacterial infection (very rare). 
Contrainidications: pregnancy. breast-feeding. 
Pregnancy is recommended to be excluded in female patients two weeks prior 
to commencement of lsotretinoin, and patients should use two simultaneous forms 
of effective contraception at least one month prior to commencement, during, and 
for at least one month following isotretinoin therapy. Women of childbearing age 
should either abstain from sexual intercourse or use 2 effective methods of birth 
control for at least 1 month before, while taking, and for 3 years after taking 
Acitretin. 
lmmunosuppresive drugs 
Methotrexate (MTX) is an antimetabolite and antifolate drug. MTX 
competitively inhibits dihydrofolate reductase (DHFR), which converts 
dihydrofolate to tetrahydrofolate, which is a necessary cofactor in the synthesis of 
thymidylate and purine nucleotides, which are required for DNA/RNA synthesis; 
increases local tissue concentrations of the potent anti-inflammatory mediator 
adenosine (by inhibiting aminoimidocarboxyamido-ribonucleotide transfor-
mylase); reduces production of the proinflammatory mediator S-adenyl methionine 
(by inhibiting methionine synthase ). MTX also exerts partially reversible 
inhibition ofthymidylate synthetase, inhibiting cell division in the S phase. 
Indications 
\.1TX is use for severe, debilitating or recalcitrant psoriasis, pityriasis rubra 
pilaris (PRP), pityriasis lichenoides et variolifonnis acuta (PLEVA), 
lymphomaloid papulosis, R~iter's disease. dermatornyositis and sarcoidosis, 
certain types of vasculitic, neutrcphilic and immunobullous dcrmatoses, in 
particular bullous pemphlgoid. 
Dosages 
MTX is administered as a once-weekly dose of up to 30 mg (individually for 
each disease) in three doses over 24 hours (8 a.m. and 8 p.m. day I, and 8 a.m. day 
2). Once disease control has been attained for at least 1-2 months, the MTX can be 
tapered by 2.5 mg every 1-2 weeks to the lowest dose that still maintains disease 
control. Intramuscular, subcutaneous administration is available. 
Contraindications 
Absolute contraindications to MTX use are pregnancy and lactation. 
Relative contraindications include significant liver disease or elevated liver 
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enzymes and excessive alcohol intake. The presence of active infection or 
immunodeficiency, and the desire for imminent pregnancy are relative 
contraindications to VITX therapy. In the elderly, serum creatinine levels may be 
deceptively low and may not reflect true renal function. 
Side effects 
The most important side effects of MTX include pancytopcnia (typically 
develops early) and hcpatotoxicit)' (the higher the cumulative dose of MTX, the 
greater the risk of significant liver damage). Compounding risk factors for hepatic 
impainnent include: previous or current excessive alcohol intake, persistent 
abnormal liver chemistries, a history of liver disease (including hepatitis B and C 
viral infections), family history of inheritable liver disease. diabetes mellitus. 
obesity, and a history of significant exposure to hcpatotoxic drugs or chemicah. 
Photosensitivity and ga<;trointestinal intolerance may occur. \1TX may cause 
reversible oligospennia in very high doses. 
Azathioprine (lmuran, Azasan) is a parent's of drug 6-mercaptopurine (6-
MP) and is moderately potent anti-inflammatory and immunosuppressive effects. It 
should be reserved for more serious, life-threatening or recalcitrant dermatoses 
after other therapies have failed. 
Mechanism of Action 
The active metabolite of azathioprine (6-Thioguanine) is a purine analogue 
similar in structure to both adenine and guanine. Incorporation of 6-thioguanine 
into D:'\A and R~A inhibits purine metabolism and cell division. 6-Thioguaninc 
has other activities which are not well understood, such as suppression of T-cell 
function and B-cell antibody production. It also decreases the number of 
Langerhans cells in the skin and inhibits their ability to present antigens. 
Indications 
Azathioprine is most often used as a corticosteroid-sparing agent in the 
treatment of immunobullous diseases such as pemphigus vulgaris, bullous 
pemphigoid and cicatr icial pemphigoid, cutaneous vasculitis, severe, recalcitrant 
atopic dermatitis and chronic actinic dermatitis in adult'>, connective tissue 
diseases such as SLE and dermatomyositis, it may improve the cutaneous 
manifestations as well. There may be a delay of 4-6 weeks in the onset of full 
clinical benefits. 
Dosages 
Available in 25, 50, 75 and 100 mg tablels, empmc dosing is generally 
started at 50 mg/day and increased to a maximum of 2.5 mg/kg/day according to 
clinical efficacy and careful monitoring. 
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Contraindications 
Absolute contraindications to azathioprine therapy include the history of a 
hypersensitivity reaction. Active serious infection and pregnancy are relative 
contraindications. 
Side Effects 
Major side effects are related to the immunosuppressive effects of 
azathioprine: Pancytopenia, increased risk for malignancies, especially 
lymphoproliferative disorders and squamous cell carcinomas of the skin and 
female genitourinary tract, life-threatening hypersensitivity reaction, which most 
commonly develops during the first month of therapy and when the drug is used in 
combination with cyclosporine or methotrcxate. 
Cyclosporine is a cyclic peptide of 11 amino acids, and has clinical 
immunosuppressivc effects. Two forms are available, the original preparation 
(Sandimmune) and a predigested microemulsion (Neoral ) that is more completely 
and consistently absorbed. 
Mechanism of Action 
Cyclosporine binds to cyclophilin, a member of the family of 
intracytoplasmic proteins called immunophilins. This complex blocks the 
dephosphorylation of NFATc and the subsequent upregulation of IL-2 and IL-2 
receptors, resulting in a decrease in the number of CD4 ' and CDS · (cytotoxic) T 
cells in the epidermis. 
Dosages 
Cyclosporine is best used on a short-term basis (<6-12 months) to control 
flares of psoriasis and to provide an alternative to the patient's current regimen. It 
is reasonable to use cyclosporine as sequential therapy with acitretin, mcthotrcxate 
or other systemic therapies. After psoriasis clearance has been initiated by 
cyclosporine, the alternative medicine may be started and advanced to the 
therapeutic dose. At the same time, cyclosporine may be weaned by I mg/kg/day 
each month until the patient is receiving acitretin or methotrexate alone. 
Historically, the maximum dermatologic dose for cyclosporine is 5 mg/kg/day. 
Indications 
Cyclosporine can be beneficial for patients with psoriasis who have failed or 
cannot tolerate other therapies and for those with widespread, atopic dermatitis, 
severe pyoderma gangrenosum, 
Contraindications 
Absolute contraindications: significant renal impairment, uncontrolled 
hypertension, and hypersensitivity to cyclosporine. Relative contraindications: age 
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< 18 years or >64 years. controlled hypertension, and medication usage that may 
interfere with cyclosporine metabolism or worsen renal function. 
Side Effects 
Cyclosporine is associated with a wide variety of adverse effects, including 
hypertension, hepatotoxicity, myositis, hyperlipidemia, hypertrichosis, gingival 
hyperplasia and renal failure. Patients with skin diseases on cyclosporine for less 
than 2 years and on lower 'dermatologic' doses have not been observed to have a 
similar risk. 
Biologicals 
Biologicals arc novel compounds composed of antibodies or other peptides that act 
through one of three mechanisms: inhibiting inflarrunatory cytokine signaling (typically 
tumor necrosis factor or TNF ), inhibiting interleukins, T -cell activation, or depleting B-
cells. They arc being used more frequently to trea1 a multitude of systemic inflammatory 
conditions. In the past ten years, biologic drugs have emerged as an important 
advance in the treatment of inflammatory disease such as rheumatoid arthritis, 
juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, plaque 
psoriasis. Crohn's disease and ulcerative colitis. 
Classification 
Biologies are divided into three groups: 
I. Recombinant human cytokines and growth factors (Interferon a (IFNa), 
Interferon y (IFNy), Interleukin 1 Receptor antagonist (ILlRa), Interleukin 2 
(IL-2), Interleukin 4 (rhlL-4), Interleukin 10 (rhlL-10), Interleukin 11 (rhlL-
11 }, Granulocyte macrophage colony stimulating factor (GM-CSF), Platelet 
derived growth factor (PDGF). 
2. Monoclonal antibodies 
• Anti-TNFa: lnfliximab, Adalimumab, Certolizumab, Golimumab 
• Anti-IS A I: Efalizumab 
• Anti-CD20: Rituximab 
• Anti-IL-12 and anti-IL-23 monoclonal antibody: Ustekinumab 
• Anti-CD2 antibody: Siplizumab 
• Anti-CD4 antibody: Orthoclone (0KTcdr4a) 
• Anti-CD25 antibodies: Basiliximab, Daclizumab 
• Anti-CD80r: Galiximab (IDEC 114) 
• Anti-IgE: Omalizumab 
3. Fusion antibody proteins (Fusion proteins, also known as chimeric proteins) 
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• Etanercept 
• Alefacept 
• Abatacept 
lnniximab (a chimeric monoclonal anti-TNF antibody) (Remicade®), 
adalimumab (a fully human anti-TNF monoclonal antibody) (Humira®), and 
etanercept (a recombinant soluble decoy TNF-receptor) (Enbrel®) exert 
therapeutic effects via the suppression of TNF-a, a cytokine released by 
macrophages that is central to cell-mediated immunity. 
Ustekinumab (Stelara®), is a fully human monoclonal antibody that binds 
with high specificity and affinity to the cytokines interleukin (IL)-12 and IL-23, 
thereby suppressing IL-12- and IL-23-mediated inflammation associated with 
psoriasis . 
Indications for the biological treatment: autoimmune disorders. 
Psoriasis: Unresponsive cases to standard therapy or significant, 
coexistant, unrelated comorbidity which precludes the use of systemic agents such 
as cyclosporine or methotrexate. 
• in psoriatic arthritis 
• severe, unstable, life-threatening clinical form of psoriasis: erytbrodermic or 
pustular psoriasis 
Standard therapy for psoriasis treatment could be, for example proposed 
by the British Association of Dermatology guidelines t.he following: 
• Acitretin 25 to 50 mg daily or; 
• Cyclosporine 2.5 to 5 mg per kg daily or; 
• Methotrexate single weekly dose (oral, subcutaneous, intramuscular) 15 mg, 
max 25 to 30 mg or; 
• Narrow band lJVB or psoralen photochemotherapy (non-response, rapid 
relapse, or exceeding recommended maximum doses) 150 to 200 treatments for 
PUV A, 350 treatments for narrowband UVB. 
Other Autoimmune skin disorders: pemphigus vulgaris, lichen planus. 
Side effects: 
I . Risk of malignancy: TNF-alpha inhibitors are associated with some degree of 
risk for lymphoma, breast cancer, colorectal cancer, melanoma, leukemia, and 
head and neck cancers in smokers. Alefacept is associated with solid organ 
malignancies, lymphomas, and melanomas. Ustekinumab is associated with 
breast, colon. head and neck, kidney, prostate. and thyroid cancers. 
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2. The infectious complications associated with immune modulation are even 
more important. Of particular concern is the risk for developing atypical and 
opportunistic infections including tuberculosis, herpes zoster, Legionella 
pneumophila, and Listeria monocytogenes. 
Miscellaneous 
Dapsone is a sulfone drug, and sulfones are related to the sulfonamide 
family. Dapsone is effective against tuberculosis and leprosy. Since 1953, dapsone 
(the parent compound of sulfoxone) has been the mainstay of treatment for 
dermatitis herpetiformis. Dapsone has also proven useful in the treatment of 
several forms of autoimmune bullous diseases and vasculitis syndromes. 
Mechanism of Action 
Dapsone inhibits neutrophil myeloperoxidase, thus reducing damage from 
the neutrophil respiratory burst mediated by this enzyme. Furthermore, dapsone 
ha~ been shown to inhibit neutrophil chemotaxis to N-formyl-methionyl-leucyl-
phenylalanine and to interfere with the CDl lb/CD IS-mediated neutrophil binding 
that induces chemoattractant signal transduction. lgA adherence is also inhibited. It 
is of clinical interest that dapsone also inhibits eosinophil myeloperoxidase 
activity. 
Indications 
Dapsone is very useful in diseases such as HD (herpetiform dermitatis), 
linear lgA bullous dermatosis, bullous eruption of SLE and erythema elevatum 
diutinum, other autoimmune bullous diseases (e.g. pempbigus foliaceus, bullous 
pemphigoid) and selected vasculitic syndromes. 
Dosages 
Dapsone is available in 25, 50 and 100 mg tablets. The initial dose is often 
50 mg/day in a single dose. Most conditions require 50-200 mg/day for adequate 
control of symptoms; rarely are dosages up to 300 mg/day required. 
Contraindications 
The absolute contraindication to dapsone therapy is prior hypersensitivity to 
dapsone. Relative contraindications include a low glucose-6-phosphate 
dehydrogenase (G6PD) level, significant cardiopulmonary disease. and an allergy 
to sulfonamide antibiotics (because of the possibility of cross-reactivity). 
Side Effects 
Serious systemic side effects of dapsone are ethemoglobinemia and 
hemolytic anemia, agranulocytosis, peripheral neuropathy and dapsonc 
hypersensitivity. 
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Antimalarials 
The most common antimalarials are hydroxychloroquine (Plaquenil®), 
chloroquine (Aralen®) 
Mechanism of Action 
The mechanism of action of the antimalarials is not well known (can inhibit 
intcrleukin-2 (IL-2) release from T-helper ( CD4~) cells and may inhibit 
macrophage expression of major histoeompatibility complex (MHC) antigens) and 
so exert various anti-inflammatory effects and they decrease platelet aggregation. 
Indication 
The antimalarials is a second-line therapy for cutaneous LE, after topical or 
intralesional corticosteroids. Antimalarials are especially useful in patients with 
widespread discoid lesions and in those with the annular or papulosquamous 
lesions of subacute cutaneous LE (SCLE). Other diseases are: polymorphous light 
eruption, sarcoidosis, lichen planus 
Dosages 
Most conditions will respond to dosages between 200 and 400 mg per day of 
hydroxychloroquine or 250 mg per day of chloroquine, 
Contraindications 
The only true contraindication is hypersensitivity to the drug. Caution should 
be used in patients with severe blood dyscrasias or hepatic disorders, because 
hepatitis and bone marrow suppression can occasionally occur. 
Side Effects of antimalarials are reversible (early) pancytopenia, hemolysis, 
irreversible retinopathy, vision changes. 
Antifungal agents 
Topical antifungal agents 
There is a wide variety of topical antifungal agents but there is no truly 
effective topical agent for onychomycosis, although nail varnishes are now 
available. The spectrum of action of topical anti fungal agents reflex in the table 9. 
Table 10. Topical antifungal agents and their spectrum of action 
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I - Natamycin + + + 
L~midazoles (more than 20) 
~!!Ylamine_s ___ _ __ _ 
+ + + 
1 - Naftifine !- - - - ----t-- + 
+ fd erbinafin e 
r:y~oxypyridones - ---- --+------ ------+---- --- __.__ _____ __, 
~-Ciclopirox _ _ ________ + _ _ _ _ __ + __ +-___ + __ ---t 
Mor holines 
- Amorolfin + 
---- ---1----- -------+--- --- -+------
Benzylamine 
!
___::. __ Butenafine __ +_ _ _ l-=-----+-- - ----1
1
1 
Others 
L-_Tolnaftate 1 +_ ~' 
I -__ .f_!ioquinol ' -~-----+------1--
1 
- Undec~len_~ acid _ _ __ ~ __ +___ _ ___ _ _ 
_ - lodoq~nol ____ _ _ _ =I=~-------~----~ 
Ciclopirox 8% and Amorolfin (LOCERYL®) nail lacquer are used for 
treatment of onychomycosis. 
Other topical agents with antifungal action are selenium sulfide, sodium 
thiosulfate, salicylic acid and sulfur, zinc pyrithione, haloprogin, mafenide, 
propylene glycol and benzoyl peroxide. 
Systemic antifungal agents 
The prescribtion of systemic anti fungals depends on their spectrum of action (table 
10) 
Table 11. Systemic antifungals and their spectrum of action 
17.---- ---
1 .... gent -- - Spectrunl --~ - -1 
++.._ Ye~sts f--!~s-- ! 
-+---~-+-:--- ::+ ~-~+--~ 
--f;-- --- - +:-=-~---= --- . , 
Griseofulvin 
hTerbinafine 
· lntraconasol 
Griseofulvin is produced by culture of some strains of the mold 
Penicillium griseofulvum. 
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Mechanism of action: The drug binds to tubulin, interfering with microtubule 
function, thus inhibiting mitosis. The micronized fonns are better absorbed and 
distributed. 
Indications: Dermatophyte infections; griseofulvinis is not effective against yeasts 
and molds. Organism should be cultured before starting therapy. 
Dosage:Griseofulvinis is still the only agent approved for tinea capitis in children; 
it 
has been replaced in most of its other uses by the more effective imidazoles. 
Childrcn!O mg/kg daily; adults 500- 100 mg p. o. daily. 
Contraindications: Liver disease, porphyria, LE, pregnancy. 
Side effects: Hepatic toxicity, gastrointestinal bleeding, leukopenia, 
granulocytopenia, cxanthems, urticaria, photosensitivity. May trigger acute 
intermittent porphyria or systemic lupus erytht!matosus. 
Itraconazolc is a triazole antifungal drug. 
Mechanism of action: Inhibits C)1ochrome P450-dependent synthesis of 
ergosterol, a key component of fungal cell walls. Because of its ability to inhibit 
cytochrome P450, caution should be used when considering interactions with other 
medications 
Indications: Effective against dermatophytes, molds, and many yeasts. Excellent 
against Candida albicans and Candida krusei; moderately effective against other 
Candida species, cutaneous mycoses, including onychomycoses, mycoses in 
HIV /AIDS, mucocutancous and systemic candidiasis, recurrent vaginal 
candidiasis, aspergillosis, soft tissue mycoticinfections. 
Dosage. The is available as 100 mg capsules and a 10 mg/ml cherry-caramel-
flavored solution. Pediatric dosing is 3 to 5 mg/kg daily. Adult oral dosages for 
various indications are: for onychomycosis of toenails - 200 mg po qd for 12 
weeks or 200 mg po bid for I week, then 3 weeks without treatment, repeated 
twice more for a total of three pulses of therapy, tinea pedis - I 00 mg po qd for 2 
weeks or 200 mg po qd for l week, tinea corporis, tinea cruris - I 00 mg po qd for 
2 weeks or 200 mg po qd for I week 
Contraindications: Pregnancy; contraception until 4 weeks after the end of 
therapy. 
Side effects: nausea, abdominal pain, anorexia, vomiting, constipation, increase in 
liver transaminases, hepatitis, headache, dizziness, peripheral neuropathy, fatigue, 
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drowsiness, hypertension, chronic heart failure,dysmenorrhea, albuminuria, 
itching, urticaria. 
Fluconazole is a triazole antifungal drug 
Mechanism of action: Inhibits cytochrome P450-dependent synthesis of 
ergosterol, a key component of fungal cell walls. 
Indications: Effective against dermatophytes and yeasts; not maids. Effectiveness 
reduced against Trichophyton mentagrophytes, Candida glabrata, and Candida guil 
liermondii. Useful for candidiasis in almost all settings from acute vaginal to 
HIV/AIDS to chronic mucocutaneous candidiasis, dermatophyte infections, 
including onychomycoses. 
Dosage: Vaginal candidiasis: Single dose of 150 mg 
Contraindications: Severe liver disease, pregnancy and nursing; contraception 
until ?days after completing therapy. 
Side effects: Seizures, leukopenia, thrombocytopenia. Hepatic injury: monitor 
liver enzymes. Toxic epidermal necrolysis: be very cautious about continuing in 
patients developing an exanthema. 
Ketoconazoles is structurally similar to imidazole, and interferes with the 
fungal synthesis of ergosterol, a constituent of fungal eel 1 membranes 
Indications: Ketoconazole inhibits growth of dermatophytes and yeast species 
such as Candida albicans. 
Dosage: Adults with skin infections are prescribed an oral dose of 200 mg I day 
once. 
Contraindications: hypersensitivity to ketoconazole, liver diseases, pregnancy 
and lactation. 
Side effects: nausea, headache, dizziness, photophobia, paresthesia. 
thrombocytopenia, rash, itching, rarely - alopecia, urticaria, rash and other 
symptoms of allergic reactions, in rare cases, gynecomastia and reversible 
oligospermia, decrease in testosterone levels in the blood plasma, very rarely 
hepatitis develops. 
Terbinafine is a synthetic allylamine antifungal . 
Mechanism of action: Inhibits sterol biosynthesis by blocking squalene perox-
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idase causing accumulation of squalene and cell death. 
Indications: Primarily dermatophytes. 
Dosage: Cutaneous disease 250mg daily p.o. for 2-4 weeks; onychomycosis 
250 mg daily p.o. for 6- 12 weeks or interval therapy. In tinea capitis in children: 
children over 2 years old and under 20 kg- 62. 5 mg q.d, children over 2 years old 
and 20 40 kg - 125 mg q.d, children over 2 years old and under 40 kg - 250 mg 
q.d 
Contraindications: Renal or hepatic disease. 
Side effects: No common serious side effects; elevated liver enzymes. disturbed 
taste; rarely toxic epidermal necrolysis . 
The new antifumgal agents are echinocandins (caspofungin, micafungin, and 
anidulafungin) and azoles II generation such as voriconazole and fluconazole 
(ravukonazol is a fluconazole derivated ), and posaconazole and albakonazol - are 
itraconazole derived used for treatment of systemic candidasis. 
Table 12. Antifungals for systemic use 
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Dosage: Side effects l 
Cutaneous disease No common serious 
250mg daily p.o. side effects; elevated 
for 2-4 weeks; liver enzymes, di stur-
onychomycosis bed taste, rarely toxic 
250 mg daily p o. ep1derinal necrolysis 
for 6- 12 weeks or 
interval therapy. 
In tinea capitis in 
1 
children-
children over 2 
years old and J 
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Children: -Hepatic toxicity, 
10 mg/kg daily; gastrointestinal 
Adults: bleeding, leukopema, 
500- 100 mg granulocytopen 1a, 
p. o daily. exantheins. umcaria. 
I 
I 
~aconazoll' 
I 
Fluconazolr 
I 
~K<.M..,wk . 
I 
I 
I 
I 
I L __ 
mitosis. The not eff~ctive 
microniud fonns against yeasts 
are better and molds. 
absorbed and 
distrib-uted 
Inhibits All 
cytochrome P450- disorders 
dependent syn-
thesis of 
ergosterol. a key 
component of 
fungal cell walls 
Because of its 
ability to inhibit 
cytochrome P450, 
caution should be 
used when 
considering inter-
actions with other I medications 
Inhibits Candidiasis 
tinea 
cytochrome P450- dermatophytc 
dependent I infections, 
synthesis of ergo- including 
I 
sterol, a key'· onychomycoses. 
compo-nent of 
fungal cell walls. I 
Structurally Dermotophyte 
similar to ( tmea cruris , 
I imidazole, and tinea corporis. interferes with lhe tinea pedis) and fungal synthesis of l ·Candida 
ergosterol , a cons- alb1cans 
tituent of fungal infection 
ce II membranes 
I 
Pediatrlc dosing 
is 3 to 5 mgllcg 
daily 
Adult onl 
dosages: 
for 
onychomycosis of 
toenails - 200 mg 
po qd for 12 weeks 
I or 200 mg po bid for I week. then 3 
weeks without 
treatment, repeated 
twice more for a 
total of three 
pulses of therapy ; 
tinca pedis - 100 
mg po qd for 2 
weeks or 200 mg 
po qd for I week; 
tinea corporis, 
tlnea cruris: 100 
1 mg po qd for 2 , 
I weeks or 200 mg for I week 
Vaginal 
candidias1s: Single 
dose of 150 mg 
Adults with skin 
infections are 
prescribed an oral 
dose of 200 
mg/day once 
photosensitivity. Maylj 
trigger acute inter-
mittent porphyria or 
systemic lupus 
erythematosus 
nausea, abdominal 
pain, anorexia, vo-
miting. constipation, I 
mcrease in liver 
transaminases. hepa- 1 
titis, headache. dizzi-
ness, peripheral neu-
ropathy, fatigue. 
1 
drowsiness, hyper-
tension. cluonic hean j 
failure.dysmenorrhea , 
albuminuria, itching, I 
unicaria. I 
I 
Seizures, leukopenia, I 
thrombocytopenia. 
Hepatic injury : !' 
monitor liver en-
zymes. I 
Toxic epidermal nec-
rolysis : be very I 
cautious about con-
unuing m patients 'i 
developing an exan-
thcma 
nausea. headache, i 
dizziness, photo · 1 
phobia, paresthesrn , 
thrombocytopenia, / 
rash. itching. rarely - 1 
alopecia. urticaria, I 
rash and other 
_ _______ I ---- ---- -- -t~- - ------~ - t ymptoms of allergic J reactions. m rare 1 ea~ gynecomasua / 
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-i-- I land reversible olig<>=l spermia. decrease in 1 
testosterone levels m I 
-
1 the blood plasma, 1 
_Jve11· rarely hepatitis develops 
~-----~-----~--- -- -
Table 13. Indications for systemic antifungals drugs 
Chronic recurrent tinea disorder Tinea pedis: dishydroti_c_an_d--~~j 
h erkeratotic forms f------------------ ----s readin lesions _______ Tinea capitis (hair is affected) __ 
Acute tinea intllammation (vesicles, Tines ungum (total-dystrophic, proximal J 
l papules, pustules) forms) _______ ____ , 
Antiviral Agents 
Acyclovir is a synthetic purine nucleoside analogue, blocks viral DNA 
synthesis by competitively inhibiting and inactivating viral DNA polymerase. 
Valacyclovir is the prodrug of acyclovir, has an oral bioavailability 
approximately three times greater than that of acyclovir (55% versus 15-30%. 
respectively) and is also more conveniently dosed than acyclovir. 
Penciclovir is an acyclic guanosine analogue with a mechanism of action 
similar to acyclovir. It is less potent because it does not cause chain tennination of 
viral DNA, and it has a poor oral bioavailability. This medication is only available 
in topical form. 
Famciclovir is the prodrug of penciclovir. Like valacyclovir, it is converted 
to its active form in the gastrointestinal tract and liver. 
Foscarnet is an intravenous antiviral used for CMV retinitis or CMV skin 
infection in HIV-infected patients and for acyclovir-resistant herpes simplex 
infections. Foscarnet is an inorganic pyrophosphate analogue that selectively 
inhibits viral DNA polymerase. 
Docosanol, also known as behenyl alcohol, is a saturated 22-carbon aliphatic 
alcohol that exhibits antiviral activity against several lipid-enveloped viruses 
including HSY. After the virus has attached to the host cell, n-docosanol prevents 
the fusion of the HSV envelope with the plasma membrane of uninfected cells. 
Topical antiviral agents are indicated for the herpes genitalis, 
mucocutaneous herpes simplex infections. 
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Table 14. Topical antiviral agents 
I Generic name Some trade name(s)® Formulations I Acyclovir Aciclor, Aciclosina, 5% ointment, cream 
Acivir, Herpex, Vacrovir, 
Vicorax, Zovir, Zovirax, I 
l Zyclir 
I Penciclovir Denavir, Vectavir 1%cream 
I Docosanol I Abreva l0%cream 
Systemic antiviral drugs 
The systemic antiviral drugs are: Valacyclovir, Cidofovir, Famciclovir, 
Foscarnet sodium injection, Ganciclovir. 
Table 15. Comparative susceptibility ofherpesviruses to antiviral drugs 
l l Antiviral drug Viral susceptibility 
HSV-1 HSV-2 vzv 
Acyclovir ; +++ +++ ++ 
Valacyclovir +++ +++ ++ 
+ + ++ 
Cidofovir 
I 
I Famciclovir 
+++ +++ i ++ 
++ ++ + 
I 
Foscarnet 
sodium injection i . onl -+~ 
G'"""lovo•T + I + + 
Formulations 
200 mg capsules; 400 mg and 
800 mg tablets 
500 mg and 1000 mg tablets 
500 mg tablets, iv solution 1 
ml 75 mg 
125 mg, 250 mg and 500 mg 
tablets i 24 mglmL, foscarnet sodium 
hexahydratc in Water for 
lnjectio 
250 Mr capsuls, 500 mg hofizat 
for solution 
I 
I 
Acyclovir, vaiacyclovir and famciclovir are all effective against herpes 
labialis when used intermittently or suppressively, and they are all effective in 
treating herpes zoster. 
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Intravenous acyclovir is used in immunocompromised patients with 
disseminated HSY or VZV and in patients with severe herpes zoster. 
Famciclovir is indicated for herpes zoster, primary or recurrent genital 
herpes, herpes suppression in immunocompetent patients and recurrent herpes 
simplex in HIV-infected patients. 
Foscamet is an intravenous antiviral used for CMV retinitis or CMV skin 
infection in HIV-infected patients and for acyclovir-resistant herpes simplex 
infections. 
Contraindications 
Antiviral agents are contraindicated in patients with hypersensitivity to the 
drug, prodrug or any components of the formulation. Systemic antivirals need to be 
dose-adjusted for pa!ients with impaired renal function, and in patients taking 
nephrotoxic medications, renal function needs to be monitored. 
Side effects 
The maior side effects of systemic antiviral agents are: morbilliform 
eruption, Stevens-Johnson syndrome, urticaria, angioedema, nausea, vomiting, 
diarrhea, abdominal pain, aplastic anemia, leukopenia, thrombocytopenia, 
headaches. 
Physiotherapy 
The classification of skin types known as the Fitzpatrick skin type (or 
phototype) depends on the amount of melanin pigment in the skin and helps the 
doctor to prescribe phototherapy. The detection of the type of skin is very 
important in the appointment of phototherapy 
Table 16. Skin types 
Skin 
type 
Typical Features Tanning ability l 
Pale white skin, blue/hazel eyes, Always burns, does not 
r----+-b_lo_n_d/_r_e_d_h_a_ir _________ _ ~a.!_l__ __ ___ ~ 
II Fair skin, blue e es 1 Bums easily, tans p~ 
L 111 I Darker white skin Tans after initial burn 
I IV ! Light brown skin ---- -+--B-urn_s __ m_i_n_im_a_ll_y _ _ t_ans 
1 
v Brown skin ~a::!ry burns, tans. dark;y~ 
easil 
VI Dark brown or black skin Never burns, always tans 
~--- _________ __ _ _ __ d~r_l<.ly ____ _ 
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Phototherapy 
Phototherapy is nowadays one of the main methods used in dermatology. It 
can be used alone or in combination with oral and/or topical treatment. The action 
of ultraviolet radiation (see fig. 20) is exploited for the treatment of many diseases. 
The first report of the use of phototherapy in the treatment of skin disorders dates 
from 1400 BC from India when patients with vitiligo were given certain plant 
extracts (whose active ingredients included psoralens) and then exposed to the sun. 
The real interest in the use of ultraviolet (UV) irradiation in the treatment of 
various skin diseases started in the l 9th century when Niels Finsen received the 
Nobel Prize (1903) for his therapeutic results with UV irradiation in lupus vulgaris, 
the only dermatologist ever to be awarded one. 
Ultraviolet light is divided to three wavelength ranges. From longest to 
shortest, they are UVA (320 nm till 400 nm), UVB (290 nm till 320 nm), and UVC 
(200 nm to 290 nm). The shorter wavelength, the lower is the penetration and the 
greater is the energy of light. UV A and UVB directly or indirectly damage DNA 
by exciting UVB absorbing molecules or they produce free radicals that injury 
cells. 
Types of Phototherapy 
UVB-therapy (290 nm till 320 nm) - the type of immunosuppressive 
therapy that inhibits the function of Langerhance cells. Narrowband UVB -
therapy (311 nm) - it is thought to be more effective than broadband UVB in the 
treatment of skin diseases. 
Indications for UVB-tberapy: 
1. Vitiligo 
2. Psoriasis 
3. Pitiriasis lichenoid chronica 
4. Atopic dermatitis 
5. Lichen planus 
6. Alopecia areata 
7. Pruritus 
8. Mycosis fungoidcs 
Photochemotherapy (PUV A) 
(Psoralen- ultraviolet therapy) - administration of oral psoralens -
phototoxic substances (8-MOP - 8 methoxipsoralen or TMP - 4,5,8-
trimethylpsoralen). followed by irradiation with long wave ultraviolet (320 to 
400nm) (UV A), is an established, effective, widely used form of treatment 
(Psoralens + UV A = PUV A). The combination is used to treat psoriasis on the 
whole body or isolated sites such as the hands and feet. PUV A clears psoriasis for 
more than 85% of patients who use it, and it induces long remission times even 
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without maintenance therapy. PUVA- therapy is deeply penetrative but it has little 
energy. 
Topical PUV A: using of topical fotosensebilisative solutions with further 
radiation (useful! for example for palmar-plantar psoriasis). 
PUV A-bathes: 
Indications: 
I . Psoriasis 
2. A topic dermatitis 
3. Mycosis fungoides 
4. Palmoplantar pustulosis 
5. Vitiligo 
6. Alopecia areata 
7. Prurigo nodularis 
Side effects: 
I . Sun bum that increase the risk of skin cancer. 
2. Cataracta. 
3. Toxic effect to liver and kidney functions in the case ofpsoralens oral 
taking. 
UV Al long-wave (340 om-400nm) 
Unlike UVB radiation that can penetrate at the most into the papillary 
dermis, longer wavelengths in the UV A region have the capacity to reach the 
subcutis as well. Accordingly, as well as due to its lesser antiproliferative activity, 
UVB irradiation has not been established in the treatment of sclerotic disorders 
except for occasional cases of graft-versus-host disease (GvHO). 
Mechanism of action: UV Al irradiation has been shown to initiate 
apoptotic cell death in dermal T lymphocytes and dennal immunoregulation. At 
least UV A 1 irradiation induces the formation of several cytokines and soluble 
factors e.g. interleukin- I and/or interleukin-6 stimulating the synthesis of 
collagenase. 
Indications: 
I . Lupus erythematosus 
2. Sclerodenna 
3. Exacerbated atopic dermatitis 
4. Cutaneous T cell lymphoma, 
5. Parapsoriasis or mucinosis follicularis 
6. Polymorphic light eruption, actinic prurigo, the cutaneous porphyrias. 
Long Term Use and Adverse Effects 
As with other forms of UV exposure, in addition to the expected immediate 
sunburn effects, chronic NB-UVB exposure is likely to increase photoaging and 
the risk of carcinogenesis. Presently there is insufficient human data available to 
provide recommendations regarding the safe maximum NB-UVB dose. However, 
according to a dose response model it has been calculated that the long-term risk 
for carcinogenesis with its use may be less than that of PUV A therapy. After the 
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first course of one year, they recommend a resting period of three months to 
minimize the annual cumulative dose of lJVB. In children, the maximum duration 
allowed is 12 months. Subsequently, if required, only limited areas should be 
exposed. If no response is observed after six months, further therapy should be 
discouraged. Further, the risk of cutaneous malignancies in vitiligo can be reduced 
by skin saving principles. i.e. covering the parts that have rcpigmented 
satisfactorily and shielding the genitals. 
Photodinamic therapy 
Photodynamic therapy (PDT) is used clinically to treat a wide range of 
medical conditions, including age-related macular degeneration and malignant 
.::ancers. and is recognised as a treatment strategy which is both minimally invasive 
and minimally toxic. Photodynamic therapy (PDT) uses exogenously administered 
or endogenously formed photosensitizers activated by light to induce cell death via 
formation of singlet oxygen and other free radicals. 
Photodynamic therapy is a 2-step procedure. In the first step, the 
photosensitizer is administered to the patient by one of several routes ( eg, topical, 
oral, intravenous), and it is allowed to be taken up by the target cells. The second 
step involves the activation of the photosensitizer in the presence of oxygen with a 
specific wavelength of light directed toward the target tissue. Because the 
photosensitizer is preferentially absorbed by hyperprolifcrative tissue and the light 
source is directly targeted on the Iesional tissue, photodynamic therapy achieves 
dual selectivity, minimizing damage to adjacent healthy structures. For 
dermatological purposes, incoherent lamps or light-emitting diode arrays can be 
used for light activation. 
Mechanism of action. The basis of PDT is the interaction of light with 
photosensitive agents to produce an energy transfer and a local chemical effect. 
Beyond direct phototoxic effects on target tissue, photodynamic therapy with 
various photosensitizers has been shown to modify cytokine expression and induce 
immune-specific responses. Immunologic effects include the production of 
interleukin I-beta, interleukin 2, tumor necrosis factor-alpha, and granulocyte 
colony-stimulating factor. Photodynamic therapy generally has a low potential for 
causing DNA damage, mutations, and carcinogenesis. 
Photosensitizers: 5-aminolevulinic acid (ALA or /,evulan®), Methyl ester 
of ALA (Metvixia(R) cream) 
Indications for PDT in dermatology: 
Basal Cell Carcinoma 
Bowen Disease 
Squamous cell carcinoma. 
Actinic keratosis 
\1alignant Melanoma 
Mycosis Fungoides 
Kaposi Sarcoma 
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Nontumoral Applications of Topical ALA-POT: 
Psoriasis 
Acne vulgaris 
Viral warts. 
Alopecia areata 
Photoaging 
Topical ALA-PDT is speculated to be comparable with anthralin in psoriasis 
therapy and may be based on the inhibition of inflammatory cytokines. Advantages 
of this approach would be higher lesion selectivity of the PS compared with 
psoralen, deeper tissue penetration of red light compared with UV-A, and 
avoidance of generalized cutaneous photoscnsitization. 
For the treatment of acne. preferential targeting of sebaceous glands and 
Propionibacterium acnes reduction are believed to be the main mechanisms 
involved. Because P acnes has been shown to naturally accumulate porphyrins, 
blue or red light alone can also have a direct therapeutic photodynamic effect on 
the bacteria. The exact mechanisms involved in ALA photodynamic therapy for 
the treatment of photoaging arc not well known, but increased collagen synthesis 
has been demonstrated following ALA photodynamic therapy. 
Side effects: 
1. Phototoxic reactions: burning sensation or, less commonly, pruritus, is observed 
during light exposure after ALA or MAL application for photodynamic therapy 
(PDT). These sensations usually decrease rapidly once the light source is 
paused or exposure is terminated. 
2. Pigmcntary abnormalities and hypersensitivity reactions: hyperpigmentation is 
sometimes seen after photodynamic therapy. It tends lo fade over a few months. 
Hypopigmentation at treated sites ha<; also been reported. Cases of allergic 
contact dermatitis and urticaria to MAL have been reported. 
3. Systemic absorption potential: extensive topical application of ALA could 
theoretically lead to systemic absorption. In clinical trials, ALA has been given 
orally at doses of up to 120 mg/kg. Cases of increased liver enzyme levels have 
been reported in patients treated with oral doses of ALA of 30 mg/kg or mmc. 
Laser therapy 
Laser-Light Amplification by Stimulated Emission of Radiation --
produces high energy radiation. 
Lasers used in dermatology emit specific wavelengths within the UV ( 10-
400 nm), visible (400-720 nm) and IR (720-1 OOO OOO nm) portions of the 
electromagnetic spectrum. Intense pulsed light (IPL) devices emit broadband 
visible and near-IR light (400-1200 nm), whereas radiofrequency devices emit 
broadband radiofrequency energy. 
In dermatology a laser of the two types are used: low-intensity - for a laser 
therapy. and - high-intensity for laser surgery. 
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Low-intensity laser radiation has the following effects: anti-inflammatory, 
antioxidant. anesthetic, mmunomodulatory, and is used to treat atopic dennatitis. 
psoriasis. alopecia areata. 
The penetration of the laser radiation depends on wavelength. decreasing 
from the long to the short-wave radiation. 
Laser application in medicine: 
• destructive effect of biological structures and processes 
• biostimulation (in physical therapy); 
• diagnostics - the study of biological structures and processes (Doppler 
spectroscopy, cytometry, laser microscopy, etc.). 
By the active medium type laser are divided into: 
•solid (ruby, neodymium) 
•gas - HE-NE (He-Ne), CO~ ; 
•semiconductor (or diode); 
• liquid (for inorganic and organic dyes); 
• metal-vapor lasers (the most common: a copper vapor or gold). 
High-intensity is obtained using CO~. Er: Y AG-laser and argon laser. C02 
laser is mainly used in dermatology and cosmetology for laser removal 
(destruction) of nevi, warts, tum ors scars and for dennabrasion. 
Relative contraindications to the use of laser therapy are: cancer, diabetes 
mellitus, hypertension. hyperthyroidism, arrhythmias, 
Surgical treatment 
Skin lesions are easily accessible for removal or biopsy. The procedure used 
needs to be appropriate to the site and type of lesion involved. It is important also 
to keep scarring to a minimum. 
Destruction of skin lesions is carried out with: 
• E lectrocautery 
•Cryotherapy 
•Laser treatment 
This is suitable for lesions where the diagnosis is certain, as no specimen is 
available or histology. 
Cryotherapy - is the destruction of tissues by extreme cold. 
Current methods used are: 
Carbon dioxide 
Solid carbon dioxide (temperature - 64°C) is produced by allowing rapid 
expansion of the compressed gas from a cylinder. This can be mixed with acetone 
to fonn a slush that can be applied with a cotton wool bud. A solid carbon dioxide 
stick, for direct application to lesions, is produced by an apparatus using "sparkle!" 
bulbs. The lesion must be frozen solid with a 1-2 mm margin of surrounding 
tissue. After thawing the freezing cycle should be repeated. 
Liquid nitrogen ( - J 96°C) 
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This can be simply applied using a cotton wool bud dipped in the vacuum 
flask of liquid nitrogen. Freezing takes a little longer than using spray apparatus. 
Various types of such apparatus are available with different sizes of nozzle. The 
larger ones are used for seborrheoic keratoses on the back, for example, and the 
smaller sizes for small lesions on the face. Freezing takes a few seconds and after 
thawing a further application can be made if necessary. 
Nitrous oxide 
A cylinder of compressed gas is used to cool a probe to approximately -
80°C. It is usually used for the treatment of warts and requires a 30 second freezing 
cycle. 
Precautions 
Cryotherapy produces pain and inflammation. Blistering and haematoma 
may occur. This can be diminished by the practical procedures and application of a 
strong steroid cream immediately after freezing, except when treating viral warts 
as it tends to encourage proliferation of the warts. 
Damage to deeper structures is rare but may occur when freezing the deeper 
tissues--for example, treating basal cell carcinoma. 
Skin lesions suitable for freezing: Viral warts (these may require several 
treatments at two to three week intervals), seborrhoeic keratoses, papillomata and 
skin tags, dysplastic lesions (early lesions, which are potentially neoplastic or of 
low grade malignancy) Bowen's disease (if confirmed by incisional biopsy), basal 
cell carcinoma (the superficial spreading typ). 
Electrocautery 
There are two forms of treatment: 
(I) Heat from an electrically heated element, which is used for removal of 
skin tags and for treatment of the surface after curettage of warts, also seborrhoeic 
keratoses. 
(2) High energy, low current "electrodesiccation" equipment which produces 
a high energy spark that can coagulate blood vessels or destroy some more 
papillomata. A fine needle point should be used for small telangiectatic naevi or 
milia. A larger needle is used for larger surfaces, for example after curettage. 
Laser surgery 
Lasers can be used as a cutting tool and studies have shown them to be a 
very effective means of producing incisions in the skin. 
Curettage 
This is a simple way of removing epidermal lesions. A curette has a metal 
spoon shaped end with a sharp cutting edge. There are a variety of shapes and sizes 
suitable for different lesions, from large seborrhoeic keratoses or papillomata to 
smaller ones for minute keratin cysts. A specimen is provided for histology but 
completeness of removal cannot be accurately assessed. Local anaesthetic is used. 
so 
Fig.I Apple-jelly symptom. 
Fig. 2 Blashko lines. 
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Fig. 3. Skin dermatomas. 
Fig.4. White dermographism. 
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Fig.5. Red dermographism. 
Vig. 6. t:rticarial dcrmographism. 
S3 
f'ig. 7. l>ermatophytes. 
Fig. 8. Fungal hyphae. 
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Fig. 9.Sarcoptes scabiei. 
Fig. 10.TLanck cells in herpes infection. 
Hg. 11. Acantolytic cells. 
Fig. 12. Green collor in !\'I. ranis infection. 
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Fig. 13.Corall red coloration in erythrasma. 
Fig.14. Derma toskope. 
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Fig.15 Ultrasound examination of normal skin. 
Fig.16 DIF of the skin of a patient with pemphigus vulgaris. lntercellular 
deposition of lgG and CJ. 
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Fig. 17. Off of the skin of a patient with bullous pemphigoid.Linear 
deposition of lgG in the epidermal basement membrane. 
Fig.18. DIF of a patient with dermititisherpetiformis. Cranular deposition of 
lgA on dermal papillae. 
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Fig.19. DIF in patient with vasculitis. Strong vessels with IgM deposition. 
Fi2.20. Ultraviolet radiation device. 
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